

# **Cancer Incidence and Mortality in New Jersey 2004-2008**

**Cancer Epidemiology Services  
Public Health Services Branch  
New Jersey Department of Health and Senior Services**



**Chris Christie, Governor  
Kim Guadagno, Lt. Governor**



**Mary O'Dowd  
Acting Commissioner**



# Cancer Incidence and Mortality in New Jersey 2004 - 2008

Prepared by:

Xiaoling Niu, MS

Stasia S. Burger, MS, CTR

Karen Pawlish, ScD, MPH

Kevin A. Henry, PhD

John J. Graff, PhD, MS

Cancer Epidemiology Services

Public Health Services Branch

New Jersey Department of Health and Senior Services

Christina G. Tan, MD, MPH

State Epidemiologist/Acting Deputy Commissioner

Mary O'Dowd

Acting Commissioner

Chris Christie, Governor

Kim Guadagno, Lt. Governor

Cancer Epidemiology Services

New Jersey Department of Health and Senior Services

PO Box 369

Trenton, NJ 08625-0369

(609) 588-3500

<http://nj.gov/health/ces/index.shtml>

April 2011



## **ACKNOWLEDGMENTS**

The following staff of the New Jersey State Cancer Registry and the Cancer Surveillance Program of the Cancer Epidemiology Services were involved in the collection, quality assurance and preparation of the data on incident cases of cancer in New Jersey:

Pamela Agovino, MPH	Mireille Lemieux, CTR
Donna Brown-Horn, CTR	Henry Lewis, MPH
Kathleen Diszler, RN, CTR	Jie Li, MPH
Thomas English, CTR	Helen Martin, CTR
Lorraine Fernbach, CTR	Ilsia Martin, MS
Ruthann Filipowicz	Kevin Masterson, CTR
Raj Gona, MPH, MA	Nicole McAnaney
Maria Halama, MD, CTR	Carl C. Monetti
Essam Hanani, MD, CTR	John Murphy, CTR
Denise Hansen	Lisa Paddock, MPH
Marilyn Hansen, CTR	Maithili Patnaik, CTR
Joan Hess, RN, CTR	Theresa Pavlovcak, CTR
Yvette Humphries	Alicja K. Piasecki, MPH
Nicole Jackson	Gladys Pyatt-Dickson, CTR
Jamal Johnson, CTR	Karen Robinson-Fraser, CTR
Linda Johnson, CTR	Lisa M. Roche, MPH, PhD
Catherine Karnicky, CTR	Marcelina Rosario
Harrine Katz, CTR	Antonio Savillo, MD, CTR
Joan Kay, CTR	Suzanne Schwartz, MS, CTR
Jill Kelly, LPN	Celia Troisi, CTR
Fran Krol, CTR	Homer Wilcox III, MS

We also acknowledge New Jersey hospitals, laboratories, physicians, dentists, and the states of Delaware, Florida, Maryland, New York, North Carolina, and Pennsylvania who reported cancer cases to the New Jersey State Cancer Registry.

Cancer Epidemiology Services, including the New Jersey State Cancer Registry, receives support from the Surveillance, Epidemiology, and End Results Program of the National Cancer Institute under contract HHSN261201000027C ADB No. N01-PC-54405, the National Program of Cancer Registries, Centers for Disease Control and Prevention under cooperative agreement 1 U58/DP000808, and the State of New Jersey.

## TABLE OF CONTENTS

Introduction.....	1
Summary .....	2
Technical Notes .....	5
New Jersey State Cancer Registry .....	5
Data Sources And Specifications.....	7
Data Presentation .....	10
References.....	12

**TABLES**

Table 1.	Age-adjusted Incidence Rates, Males All Races Combined.....	16
Table 2.	Age-adjusted Incidence Rates, Females All Races Combined.....	18
Table 3.	Age-adjusted Incidence Rates, White Males.....	20
Table 4.	Age-adjusted Incidence Rates, White Females.....	22
Table 5.	Age-adjusted Incidence Rates, Black Males.....	24
Table 6.	Age-adjusted Incidence Rates, Black Females.....	26
Table 7.	Age-adjusted Incidence Rates, Hispanic Males.....	28
Table 8.	Age-adjusted Incidence Rates, Hispanic Females.....	30
Table 9.	Age-adjusted Incidence Rates, Asian and Pacific Islander Males and Females.....	32
Table 10.	Benign and Borderline Brain Tumor Incidence Rates, New Jersey, 2004-2008.....	34
Table 11.	Comparative Incidence Rates, New Jersey and U.S., 2003-2007.....	35
Table 12.	Comparative Incidence Rates, New Jersey and U.S., 2003-2007.....	35
Table 13.	Age-adjusted Mortality Rates, Males All Races Combined.....	36
Table 14.	Age-adjusted Mortality Rates, Females All Races Combined.....	38
Table 15.	Age-adjusted Mortality Rates, White Males.....	40
Table 16.	Age-adjusted Mortality Rates, White Females.....	42
Table 17.	Age-adjusted Mortality Rates, Black Males.....	44
Table 18.	Age-adjusted Mortality Rates, Black Females.....	46
Table 19.	Age-adjusted Mortality Rates, Hispanic Males and Females.....	48
Table 20.	Age-adjusted Mortality Rates, Asian and Pacific Islander Males and Females.....	50
Table 21.	Comparative Mortality Rates, New Jersey and U.S., 2003-2007.....	52
Table 22.	Comparative Mortality Rates, New Jersey and U.S., 2003-2007.....	52
Table 23.	Population Denominators.....	53
Table 24.	Age Distribution (%) of Incidence Cases in New Jersey, 2004-2008.....	55
Table 25.	Median Age of Cancer Patients at Diagnosis, New Jersey 2004-2008.....	56



## INTRODUCTION

This report presents statewide, age-adjusted incidence rates and counts for all cancers diagnosed among New Jersey residents during the period 2004-2008, age-adjusted mortality rates and counts for the period 2004-2007 and comparisons of state and national rates for 2003-2007. The New Jersey cancer incidence data for 2008 are considered preliminary. U.S. cancer incidence data and cancer mortality data for 2008 are not yet available.

The primary goal of this report is to provide 2004-2008 cancer data to healthcare planners, researchers and the public. Data are provided statewide for eight population subgroups: white men, white women, black men, black women, Hispanic men, Hispanic women, Asian and Pacific Islander men and Asian and Pacific Islander women. Data are also provided by gender for all races combined.

The age-adjusted incidence and mortality rates per 100,000 population are presented by major cancer sites and for all sites combined by year of diagnosis. Asian and Pacific Islander data are presented for the combined five year period of 2004-2008. For the incidence counts and rates, *in situ* cancers are not included except for bladder cancer *in situ* cases, which are included with invasive urinary bladder, urinary system and all sites. Breast cancer *in situ* cases for women are shown but not included in the totals for all sites combined. Basal and squamous cell skin cancers are not collected and therefore not included in the data tables. Benign and borderline brain tumor incidence data for 2004-2008 are presented separately. These conventions are standard practice for publication of cancer rates in the United States.

Additional New Jersey cancer incidence, mortality, survival, and prevalence data are available from the Cancer Epidemiology Services office or on our website, <http://nj.gov/health/ces/index.shtml>, including:

- *Cancer Among Asians and Pacific Islanders in New Jersey, 1990-2007*
- *Adolescent and Young Adult Cancer in New Jersey-1979-2006;*
- *Childhood Cancer in New Jersey, 1979-2005;*
- *Area Socioeconomic Variations in Cancer Incidence and Stage at Diagnosis in New Jersey, 1996-2002;*
- *Cancer Survival in New Jersey 1979-1999; and*
- *Cancer Prevalence in New Jersey on January 1, 2003*

Our interactive cancer data mapping application provides incidence counts and rates statewide and at the county level by year, age, sex, race, and ethnicity for the years 1990-2008 and mortality counts and rates for the years 1990-2006 at <http://nj.gov/health/ces/cancer-rates.shtml>. Other New Jersey and U.S. cancer data can be found on the following websites:

- Cancer Control Planet, <http://cancercontrolplanet.cancer.gov/>
- North American Association of Central Cancer Registries' *Cancer in North America 2003—2007*, <http://www.naacr.org/DataandPublications/CINAPubs.aspx>
- Surveillance, Epidemiology and End Results Program (SEER) Cancer Statistics, <http://www.seer.cancer.gov/>.

## SUMMARY

### **Cancer Incidence, New Jersey 2004-2008**

A total of 46,431 cases of invasive cancer diagnosed in 2008 among New Jersey residents were reported to the New Jersey State Cancer Registry (NJSCR), compared to 47,388 reported cases diagnosed in 2007. During the period 2004-2008, a total of 233,522 cases of invasive cancer were diagnosed among New Jersey residents, 50.5 percent among men and 49.5 percent among women, 84.5 percent among whites, 10.6 percent among blacks, and 2.9 percent among Asians and Pacific Islanders (API). Hispanics of any race accounted for 7.3 percent of the total cancer cases.

Primary cancers with the highest age-adjusted incidence rates during 2004-2008 in New Jersey were prostate, lung, colon and rectum, urinary bladder, melanoma of the skin, non-Hodgkin lymphoma, kidney and renal pelvis, leukemia, oral cavity and pharynx, and pancreas for men; and breast, lung, colon and rectum, endometrial (corpus and uterus), thyroid, melanoma of the skin, non-Hodgkin lymphoma, ovary, pancreas, and kidney and renal pelvis for women.

In New Jersey, the overall age-adjusted total cancer incidence rate for men was 584.7 per 100,000 for the years 2004-2008, with rates that increased in 2006 and 2007. Total cancer incidence rates for black men continued their steady decline and for the first time, were lower than incidence rates for white men for 2007 and 2008. Total cancer incidence rates for white men peaked in 2006 and have also continued to decline. Prostate cancer rates for black men continued to decline but are still higher than the rates for white men, which continued to increase from 2004 to 2007. Lung cancer and colorectal cancer incidence rates among all men also continued to decline. Stomach cancer incidence rates continued to slowly decrease for all men. Thyroid cancer incidence rates continued to increase with a more pronounced increase in 2008, with rates higher for white men than for black men.

The age-adjusted total cancer incidence rates for New Jersey women fluctuated slightly from 2004-2008 with an average annual incidence rate of 447.8 per 100,000 women. Total cancer incidence rates for black women slightly decreased during this time period and continued to be lower compared to white women. Breast cancer rates among all women fluctuated during this time period with a slight increase in rates among black women. Lung cancer incidence rates among all women remained fairly stable with white women having a slight increase in incidence rates and black women having a slight decrease in incidence rates for this time period 2004-2008. Colorectal cancer incidence rates among all women continued to decline while corpus uteri cancer and melanoma of the skin incidence rates increased slightly for this time period. Thyroid cancer incidence rates continue to increase for all women during 2004-2008 with the rate for white women more than double the rate for black women. Rates for melanoma of the skin among all women also increased during 2004-2007.

New Jersey Hispanics continued to have lower incidence rates for all cancers combined and for many of the most common types of cancer in the general population including lung, colorectal, female breast, prostate, bladder, and melanoma of the skin. Hispanics also continued to have higher incidence rates for cervical, stomach and liver cancers compared with the general population. For the first time, cancer incidence rates for Hispanic men and

women are presented here separately by year. Among Hispanic men, incidence rates for total cancer and for most common cancers decreased during 2004-2008. Among Hispanic women, total cancer incidence rates also decreased during 2004-2007 but slightly increased in 2008. Thyroid cancer incidence rates for Hispanic women showed an increasing trend similar to that seen among all New Jersey women.

Also for the first time here, cancer incidence data are presented for the Asian and Pacific Island (API) population. New Jersey Asians and Pacific Islanders had lower cancer incidence rates for all cancers combined and most common types of cancer. Stomach, liver and intrahepatic bile duct cancer incidence rates were higher for Asians and Pacific Islanders than in the general population.

A review of the incidence of benign and borderline brain and central nervous system tumors in New Jersey showed that they occurred mostly in intracranial meninges and the sellar region, while invasive brain tumors occurred mostly in the brain proper. This pattern was similar to the results seen in U.S. SEER data. New Jersey incidence data for 2004-2008 showed women had higher rates compared to men for these types of tumors and rates were fairly similar among whites and blacks. Women also had higher benign intracranial meningioma incidence rates compared to men during this same time period.

### **Cancer Incidence in New Jersey and U.S. 2003-2007**

Comparing New Jersey and U.S. age-adjusted incidence rates using data published in *Cancer in North America* by the North American Association of Central Cancer Registries (NAACCR) for 2003-2007, New Jersey incidence rates for all cancers combined continued to be higher than the U.S. rates. Both New Jersey men and women had higher incidence rates compared to the U.S. for the most common cancers with some exceptions. New Jersey lung cancer incidence rates for all men combined, white men, black men and API men were lower than the U.S. rates. New Jersey colorectal cancer incidence rates for black and API men were lower than the U.S. rates along with lower incidence rates for prostate cancer among API and non-Hodgkin lymphoma among Hispanics. New Jersey breast cancer incidence rates were lower than the U.S. rates for black and API women. New Jersey API women also had lower total cancer, colorectal, lung and non-Hodgkin lymphoma cancer incidence rates compared to the U.S. New Jersey colorectal cancer incidence rate for Hispanics was also lower compared to the U.S. rate.

### **Cancer Mortality, New Jersey 2004-2007**

Among New Jersey residents, a total of 17,092 deaths occurred in 2007 for which cancer was designated on the death certificate as the underlying cause, compared to 17,180 reported cancer deaths in 2006. During the period 2004-2007, a total of 68,653 cancer deaths occurred among New Jersey residents, 48.9 percent among men and 51.1 percent among women. The top cancers with the highest age-adjusted mortality rates for 2004-2007 in New Jersey were lung, prostate, and colon and rectum for men; and lung, breast, and colon and rectum for women. Overall age-adjusted cancer mortality rates for men and women in New Jersey continued to decline, reflecting the trends seen in U.S. mortality data.

New Jersey cancer mortality rates continued to be higher for men than for women during 2004-2007 (218.9 per 100,000 versus 161.2 per 100,000). This pattern was observed among all races and ethnicity groups. Cancer mortality rates for both black men and women continued to be higher compared to white men and women. Overall cancer mortality rates for New Jersey Hispanic men and women were lower than for all New Jersey men and women, except slightly higher mortality rates for liver cancer among Hispanic women and for stomach cancer among both Hispanic men and women. New Jersey APIs had much lower total cancer mortality rates than for the New Jersey total population. However, stomach and liver cancer mortality rates were higher in API men and women than in all New Jersey men and women.

### **Mortality in New Jersey and U.S. 2003-2007**

For the period 2003-2007, the New Jersey cancer mortality rates for all men for total cancer, lung, and prostate cancer, were lower than the corresponding rates for the U.S. while the colorectal cancer mortality rate for all men was slightly higher compared to the U.S. New Jersey lung and prostate cancer mortality rates were also lower than the U.S. rates for white, black, API and Hispanic men. New Jersey colorectal cancer mortality rates were higher than the U.S. rates for both white and black men but lower for API and Hispanic men. Among all New Jersey women during the same time period, the cancer mortality rates for total cancer, breast and colorectal cancers were higher compared to the U.S. rates. New Jersey mortality rates among white and black women were higher than the U.S. rates for total cancer and colorectal cancer but lower for lung cancer. Among API and Hispanic women in New Jersey, mortality rates were lower than the U.S. rates for total cancer as well as colorectal, lung and breast cancers.

## TECHNICAL NOTES

### New Jersey State Cancer Registry (NJSCR)

#### NJSCR Overview

The objectives of the NJSCR are to:

- \* monitor cancer trends in New Jersey,
- \* promote scientific research,
- \* respond to New Jersey residents about cancer concerns,
- \* educate the public,
- \* provide information for planning and evaluating cancer prevention and control activities,
- \* share and compare cancer data with other states and the nation, and
- \* participate in population based investigations of cancer etiology, prevention, treatment and outcomes.

The NJSCR is a population-based cancer incidence registry that serves the entire state of New Jersey which has a current estimated population of over 8.7 million people. The NJSCR was established by legislation (NJSA 26:2-104 et. seq.) and includes all cases of cancer diagnosed in New Jersey residents since October 1, 1978. New Jersey regulations (NJAC 8:57A) require the reporting of all newly diagnosed cancer cases to the NJSCR within three months of hospital discharge or six months of diagnosis, whichever is sooner. Reports are filed by hospitals, diagnosing physicians, dentists, and independent clinical laboratories. Every hospital in New Jersey reports cancer cases electronically. In addition, reporting agreements are maintained with New York, Pennsylvania, Delaware, Florida, Maryland, and North Carolina so that New Jersey residents diagnosed with cancer outside the state can be identified. Legislation passed in 1996 strengthened the NJSCR by requiring electronic reporting, requiring abstracting by certified tumor registrars, and establishing penalties for late or incomplete reporting.

All primary invasive and *in situ* neoplasms are reportable to the NJSCR, except cervical cancer *in situ* diagnosed after 1994 and certain carcinomas of the skin. Benign and borderline brain tumors diagnosed on or after January 1, 2004 are reportable according to Public Law 107-260, the Benign Brain Tumor Cancer Registries Act, which was signed in October 2002. The information collected by the NJSCR includes basic patient identifiers, demographic characteristics of the patient, medical information on each cancer diagnosis (such as the anatomic site, histologic type and stage of disease), first course of treatment and vital status (alive or deceased) determined annually. For deceased cases, the underlying cause of death is also included. The primary site, behavior, grade, and histology of each cancer are coded according to the *International Classification of Diseases for Oncology (ICD-O), 3<sup>rd</sup> edition* for cancers diagnosed after 2000. The NJSCR follows the data standards promulgated by the North American Association of Central Cancer Registries (NAACCR), including the use of the Surveillance, Epidemiology, and End Results (SEER) multiple primary rules. An individual may develop more than one cancer. Following the SEER multiple primary rules,

patients could therefore be counted more than once if they were diagnosed with two or more primary cancers.

The NJSCR is a member of the NAACCR, an organization that sets standards for cancer registries, facilitates data exchange, and publishes cancer data. The NJSCR has been a participant of the National Program of Cancer Registries (NPCR) sponsored by the Centers for Disease Control and Prevention (CDC) since it began in 1994 and is a National Cancer Institute (NCI) SEER Registry.

### **NJSCR Data Quality**

NAACCR has awarded the Gold Standard, the highest standard possible, to the NJSCR for the quality of the data for each year 1995 through 2007. The NJSCR has consistently achieved the highest level of certification for its data since the inception of this award. The criteria used to judge the quality of the data are completeness of cancer case ascertainment, completeness of certain information on the cancer cases, percent of death certificate only cases, percent of duplicate cases, passing an editing program, and timeliness.

Completeness of reporting to the NJSCR was estimated by comparing New Jersey and U.S. incidence to mortality ratios for whites and blacks, standardized for age, gender, and cancer site. The data used to generate these ratios were the cancer incidence rates for all SEER registries combined. Using these standard formulas, it is possible for the estimation of completeness to be greater than 100 percent. For 2008 data, the completeness of case reporting was estimated as 106 percent at the time this report was prepared.

While our estimates of completeness are very high, some cases of cancer among New Jersey residents who were diagnosed and/or treated in out-of-state facilities may not yet have been reported to the NJSCR by other state registries. This should be considered in interpreting the data for the more recent years. However, these relatively few cases will not significantly affect the cancer rates, or alter the overall trends presented in this report.

Other 2008 cancer incidence data quality indicators measured as follows:

- percent death-certificate-only cases: 1.4 percent;
- percent of unresolved duplicates: < 0.1 percent;
- percent of cases with unknown race: 1.3 percent;
- percent of cases with unknown county: 0.1 percent;
- number of cases with unknown age: 1; and
- number of cases with unknown gender: 0.

It should also be noted that there may be minor differences in the New Jersey incidence and mortality rates in this report compared to previous reports, due to delayed reporting, ongoing editing and reviewing of the data. The population denominators also affect the incidence rates. The 2007 incidence rate for total cancer in this report increased by 1.5% and 1.0% for men and women, respectively compared with last year's report. The 2008 incidence rates are

considered preliminary since case counts are expected to change by the time all data are complete.

The NJSCR continues to work toward improving the quality and number of its reporting sources. Over the past few years, significant improvements have been realized in this regard. For example, some of these improvements have resulted in better reporting of skin cancers such as melanoma. One of the most significant improvements has been the implementation of electronic pathology laboratory reporting (E-path) from a national pathology laboratory and several hospital-based laboratories. The ultimate goal is to enable E-path laboratory reporting from every laboratory that serves New Jersey. E-path reporting has improved the timeliness and completeness of cancer reporting, especially for non-hospitalized cases.

One limitation that could affect New Jersey cancer incidence data is the recent federal formal restrictions on the submission of cancer cases from Veteran's Health Administration (VA) hospitals to cancer registries. NJSCR received 0.6% of the total cases exclusively from VA hospitals for the years 2004 and earlier. Since then, the NJSCR received only 0.3% of the total cases from VA hospitals for 2005 and no cases for 2006 through 2008. The impact of missing VA hospital cases in New Jersey could result in underestimates of cancer incidence rates for men in 2005 through 2008.

## **Data Sources and Specifications**

### **Incidence Data**

New Jersey cancer incidence data were taken from the December 2010 analytic file of the NJSCR. All the counts and rates were tabulated using SEER\*Stat Version 6.6 (<http://www.seer.cancer.gov/seerstat/>), a statistical software package distributed by the NCI. U.S. cancer incidence data were obtained from NAACCR's publication, *Cancer in North America 2003-2007* (<http://www.naacr.org/DataandPublications/CINAPubs.aspx>).

The cancer categories in this report are based on the primary site and histology data fields abstracted from the medical records. For detailed definitions of the cancer categories, please visit the SEER program website ([http://www.seer.cancer.gov/siterecode/icdo3\\_d01272003/](http://www.seer.cancer.gov/siterecode/icdo3_d01272003/)). We used the cancer site recode with mesothelioma and Kaposi sarcoma in separate categories.

Benign and borderline brain tumors are classified into six groups by primary site: brain, intracranial meninges, cranial nerves and other central nervous system, tumor of the sellar region (pituitary gland, craniopharyngeal duct, and pineal gland), spinal cord, and spinal meninges.

The coding scheme for incident cancer cases in this report is derived from *International Classification of Diseases for Oncology, 3<sup>rd</sup> edition (ICD-O-3)*. There are some reportability changes from ICD-O-2 to ICD-O-3. When cases in 1979-2000 are converted from ICD-O-2 to ICD-O-3, some cancers (mainly ovarian cancer) yield an ICD-O-3 borderline behavior. Also, when 2001 or later cases are converted from ICD-O-3 to ICD-O-2, some cancers yield an ICD-O-2 borderline behavior. We used SEER behavior recode for analysis to select invasive cancers. For the definition, visit SEER Behavior Recode for Analysis on the SEER website: <http://www.seer.cancer.gov/behavrecode/>. Using this definition, only those invasive cancers

that had a behavior of malignant in both ICD-O-2 and ICD-O-3 are presented in the tables, except the benign and borderline brain tumor table.

### **Exclusions**

For this report, cases where the county of residence is unknown were excluded from the New Jersey rates and counts, in accordance with standard procedures used by SEER, and has been determined to have little effect on the incidence rates. For example, the total number of cases with unknown county for 2004-2008 is 115, representing 0.05% of the total case population. The small numbers of cases with unknown age or gender were also excluded from the analyses. Since the number of records affected was very small, the rates were virtually unaffected by the exclusion of these records. Race-specific information is not shown separately for persons who are races other than white, black, or Asian and Pacific Islander (including unknown race), but these persons are included in the “all races” data.

Only invasive cancers were included in the incidence tables 1 to 7, 9-10 and 21-22, except *in situ* bladder cancers were included. Invasive means that a case had malignant behavior in both ICD-O-2 and ICD-O-3. Some invasive cancers were excluded from the analysis by this definition. Myelodysplastic syndrome, for example, was reclassified in ICD-O-3 (effective diagnosis year 2001) from nonmalignant to malignant; other cancers so reclassified include endometrial stromal sarcoma (low grade), papillary ependymoma, papillary meningioma, polycythemia vera, chronic myeloproliferative disease (NOS), myelosclerosis with myeloid metaplasia, essential thrombocythemia, refractory anemia, refractory anemia with sideroblasts, refractory anemia with excess blasts, and refractory anemia with excess blasts in transformation. In contrast, borderline tumors of the ovary were reclassified from malignant to nonmalignant at the same time, and these cancers were excluded from the analysis. Starting with diagnosis year 2001, pilocytic astrocytoma was reclassified as malignant and was not excluded. For 2008 cases, a total of 720 were excluded. These exclusions are consistent with NCI SEER program publications. The total cancer counts and rates were lower with these exclusions than the data presented in other sources (CDC Cancer Control Planet and NAACCR publications).

### **Mortality Data**

New Jersey cancer mortality data in 2004-2007 were obtained through the NCI SEER Program from the National Center for Health Statistics (NCHS) and tabulated using SEER\*Stat. At the time of this report, year 2008 mortality data were not yet available.

Cancer sites in mortality data were grouped according to the revised SEER Cause of Death Recode 1969+ (9/17/2004). The detailed information can be found on the SEER website (<http://seer.cancer.gov/codrecode/>). U.S. cancer mortality data were obtained from NAACCR's publication, *Cancer in North America 2003-2007* (<http://www.naacr.org/DataandPublications/CINAPubs.aspx>).

### **Population Data**

The 2003-2008 New Jersey population estimates for this report were provided by the NCI's SEER Program released on January 21, 2011 and downloaded from the SEER website

(<http://www.seer.cancer.gov/popdata/download.html> ). The population estimates incorporate new Vintage 2009 bridged single-race estimates for July 1, 2000-2009 that are derived from the original multiple race categories in the 2000 Census (as specified in the 1997 Office of Management and Budget standards for the collection of data on race and ethnicity). The bridged single-race estimates and a description of the methodology used to develop them are available on the National Center for Health Statistics (NCHS) Web site ([http://www.cdc.gov/nchs/nvss/bridged\\_race.htm](http://www.cdc.gov/nchs/nvss/bridged_race.htm) ). The new vintage 2009 bridged single-race populations result in a general downward shift of the latest post-censal populations compared with the Vintage 2008 population. This general downward shift in the populations causes a general upward shift in disease rate calculations based on these new populations. For the cancer incidence rates presented in this report, the rates were 0.4 percent higher using the new population compared with the rates in last year's report. For the impact on mortality rates, see discussion on Vintage 2009 impact on rates SEER website ([http://www.seer.cancer.gov/popdata/impact\\_rates\\_2009.html](http://www.seer.cancer.gov/popdata/impact_rates_2009.html)).

### **Description of Algorithm for Designating Hispanic Ethnicity**

In 2003, the NJSCR adopted the NAACCR Hispanic Identification Algorithm (NHIA) to assign Hispanic ethnicity to cases. This method uses data on birthplace, marital status, gender, race and surname match to the 1990 Hispanic surname list to augment the number of cases and decedents reported as Hispanic in the registry during the years 1990-2004.

In 2005, NAACCR made several revisions to NHIA, now NHIA version 2. The most significant change in NHIA version 2 was the addition of an option for registries to not apply the algorithm to counties in which the Hispanic population is less than five percent. The NJSCR determined that this option did not enhance the accuracy of the NHIA and therefore opted not to apply this option. Thus, using NHIA version 2 will not affect the New Jersey cancer rates among Hispanics.

Prior to the development of the NHIA, the NJSCR used a method to assign Hispanic ethnicity to cases that was adapted from algorithms developed by the Illinois State Cancer Registry (ISCR) and by the NJSCR. NHIA is closely related to these former algorithms, so there is high agreement between the cases previously determined to be Hispanic and those currently determined to be Hispanic.

As a result of using the NHIA, the NJSCR was able to increase the number of Hispanic cases by 22 percent for this time period, thereby correcting an under-identification of Hispanics. For a more complete description of the NHIA version 2 and a copy of the NHIA SAS program visit the following link at the NAACCR website:  
<http://www.naacr.org/datastandards>.

Caution should be used when comparing rates among Hispanics with the rates in the different race groups (e.g., black, white) because ethnicity and race are not mutually exclusive. In New Jersey, the majority (89 percent) of Hispanics identify themselves as white. The Hispanics who identify themselves as white or black are included in the white or black race category as well as the all races category.

Caution should also be used when comparing Hispanic mortality data to Hispanic incidence data in this report. Hispanic mortality data for this report were obtained from NCI's SEER Program and did not have the NHIA algorithm applied to them. In our detailed report, *Cancer Among Hispanics in New Jersey, 1990-1996*, our previous Hispanic algorithm was applied to mortality data from the New Jersey Center for Health Statistics, resulting in an increased mortality rate of 13 percent for men and 23 percent for women.

## **Data Presentation**

### **Suppression of Rates and Counts under Five**

It should also be noted that the annual rates for relatively uncommon cancers tend to fluctuate substantially from year to year because of small numbers of cases, particularly in minority populations. Rates generated from small numbers should be interpreted with caution. For this report, rates were suppressed where counts were less than five as a way to ensure statistical reliability and patient confidentiality.

### **Calculation of Rates**

All the counts and rates were tabulated using SEER\*Stat Version 6.6 (<http://www.seer.cancer.gov/seerstat/>), a statistical software package distributed by the National Cancer Institute. U.S. cancer incidence and mortality data were obtained from NAACCR's publication, *Cancer in North America 2003-2007* (<http://www.naacr.org/DataandPublications/CINAPubs.aspx>).

### **Age-adjusted Rates and the Year 2000 Standard**

The U.S. Department of Health and Human Services requires that health data be age-adjusted using the U.S. Year 2000 population as a standard, beginning with the 1999 reporting year. Age-adjustment to the year 2000 population as the standard has been used in our last seven annual reports. Prior to the release of 1999 data, various federal and state agencies calculated disease rates using different U.S. population standards, including the 1940 and 1970 standard populations. Our report *Cancer Incidence and Mortality in New Jersey, 1995-1999*, issued in September 2001, used the former 1970 population standard for all five years and also illustrated the effect on 1999 incidence rates of changing the population standard from 1970 to 2000.

Calculations using the 2000 standard population do not indicate a change in cancer incidence or occurrence—only a different representation of the rates of reported cancer. Using the 2000 population as the standard produces standardized cancer rates that appear to be about 20 percent higher than previously reported.

In this report, the 2000 U.S. Standard Population (19 age groups-Census P25-1130) was used for age-adjustment instead of the 2000 U.S. Standard Million (19 age groups). This has been standard practice for all NCI SEER reports with incidence or mortality data for 2002 or later.

This new population standard was created for use with single year of age population data. Differences in the age-adjusted rates using the 2000 Standard Million and the new 2000 U.S. Standard Population are minimal. For further details, see SEER's website located at the following link: [http://seer.cancer.gov/stdpopulations/single\\_age.html](http://seer.cancer.gov/stdpopulations/single_age.html).

### **Rate Calculation Formulas**

A cancer incidence rate is defined as the number of new cases of cancer detected during a specified time period in a specified population. Cancer rates are most commonly expressed as cases per 100,000 population. Cancer occurs at different rates in different age groups, and population subgroups defined by gender and race have different age distributions. Therefore, before a valid comparison can be made between rates, it is necessary to standardize the rates to the age distribution of a standard population.

The first step in the age-standardization procedure is to determine the age-specific rates. For each age group for a given time interval (within each race-gender group, for the entire state), the following formula is applied:

$$r_a = \frac{n_a}{t \times P_a}$$

where

- $r_a$  = the age-specific rate for age group a,
- $n_a$  = the number of events (cancer diagnoses) in the age group during the time interval,
- $t$  = the length of the time interval (in years), and
- $P_a$  = average size of the population in the age group during the time interval (mid-year population or average of mid-year population sizes).

In order to determine the age-adjusted rate, a weighted average of the age-specific rates is calculated, using the age distribution of the standard population to derive the age-specific weighting factors (Rothman, 1986). This is the technique of direct standardization which uses the following formula:

$$R = \frac{\sum_{a=1}^n r_a \times Std. P_a}{\sum_{a=1}^n Std. P_a}$$

where

- $R$  = the age-adjusted rate,
- $r_a$  = the age-specific rate for age group a, and
- $Std.P_a$  = the size of the standard population in each age group a.

While age standardization facilitates the comparison of rates among different populations, there can be important age-specific differences in disease occurrence, which are not apparent in comparisons of the age-adjusted rates (Breslow and Day, 1987).

Analogous definitions and calculations apply for cancer mortality rates.

## REFERENCES

- Breslow NE and Day NE. *Statistical Methods in Cancer Research. Volume II – The Design and Analysis of Cohort Studies*. New York: Oxford University Press, 1987.
- Centers for Disease Control and Prevention. *Data collection of primary central nervous system tumors. National Program of Cancer Registries Training Materials*. Atlanta, Georgia: Department of Health and Human Services, Centers for Disease Control and Prevention, 2004.
- Chiang CL. "Standard error of the age-adjusted death rate". In *Vital Statistics Special Reports, Volume 47, Number 9*. USDHEW, PHS, Washington, D.C. U.S. Government Printing office, 1961.
- Copeland G, Lake A, Firth R, et al. (eds). *Cancer in North America: 2003-2007. Volume One: Combined Cancer Incidence for the United States and Canada*. Springfield, IL: North American Association of Central Cancer Registries, Inc. May 2010.
- Edwards BK, Ward E, Kohler BA, et al. Annual Report to the Nation on the Status of Cancer, 1975-2006, Featuring Colorectal Cancer Trends and Impact of Interventions (Risk Factors, Screening, and Treatment) to Reduce Future Rates. *Cancer*. Published online Dec. 7, 2009. DOI: 10.1002/cncr.24760.
- Ingram DD, Parker JD, Schenker N et al. United States Census 2000 population with bridged race categories. National Center for Health Statistics. *Vital Health Stat 2(135)*. 2003. [URL. [http://www.cdc.gov/nchs/data/series/sr\\_02/sr02\\_135.pdf](http://www.cdc.gov/nchs/data/series/sr_02/sr02_135.pdf), accessed December 7, 2010]
- Martin, RM. "Age standardization of death rates in New Jersey: Implications of a change in the standard population". *Topics in Health Statistics*. Center for Health Statistics. 2000;01-02.
- National Center for Health Statistics. U.S. census population with bridged race categories, August 2008. [URL. [http://www.cdc.gov/nchs/nvss/bridged\\_race.htm](http://www.cdc.gov/nchs/nvss/bridged_race.htm), accessed February 7, 2011]
- NAACCR Race and Ethnicity Work Group. *NAACCR Guideline for Enhancing Hispanic/Latino Identification: Revised NAACCR Hispanic/Latino Identification Algorithm [NHIA v2.2.1]*. Springfield (IL): North American Association of Central Cancer Registries. September 2010. [URL. <http://www.naacr.org/DataandPublications/CallforData.aspx>, accessed December 7, 2010]
- Rothman K. *Modern Epidemiology*. U.S. Little, Brown, and Company. 1986.
- Surveillance Research Program, National Cancer Institute SEER\*Stat software ([www.seer.cancer.gov/seerstat](http://www.seer.cancer.gov/seerstat)) version 6.6.2. March 25, 2010.
- Surveillance, Epidemiology, and End Results (SEER) Program ([www.seer.cancer.gov](http://www.seer.cancer.gov)) SEER\*Stat Database: Mortality - All COD, Aggregated With State, Total U.S. (1990-2007) <Katrina/Rita Population Adjustment>, National Cancer Institute, DCCPS, Surveillance

Research Program, Cancer Statistics Branch, released June 2010. Underlying mortality data provided by NCHS ([www.cdc.gov/nchs](http://www.cdc.gov/nchs)).

Surveillance, Epidemiology, and End Results (SEER) Program ([www.seer.cancer.gov](http://www.seer.cancer.gov))  
SEER\*Stat Database: Populations - Total U.S. (1969-2009), National Cancer Institute, DCCPS, Surveillance Research Program, Cancer Statistics Branch, released January 21, 2011. [URL. <http://seer.cancer.gov/popdata/>, accessed February 3, 2011]

Weinstein R, Lee YS and Klotz J. *Cancer Among Hispanics in New Jersey 1990-1996*. New Jersey Department of Health and Senior Services, June 2000. [URL. <http://www.state.nj.us/health/cancer/hispanic/>, accessed October 26, 2005]



**TABLES**

**Table 1. Age-adjusted Incidence Rates, Males All Races Combined**

Cancer Site	Rates					Cases 2004-2008	Rates
	2004	2005	2006	2007	2008		
<b>All Sites</b>	582.0	581.9	600.8	601.2	557.8	118,029	584.7
<b>Oral Cavity and Pharynx</b>	14.5	14.4	15.5	15.2	13.8	3,132	14.7
Lip	0.4	0.5	0.4	0.7	0.5	100	0.5
Tongue	4.5	4.3	5.2	4.8	4.4	1,009	4.7
Salivary Gland	1.6	1.7	1.9	1.9	1.9	360	1.8
Floor of Mouth	0.8	0.8	0.8	1.0	0.6	174	0.8
Gum and Other Mouth	1.9	1.7	2.0	1.8	1.7	378	1.8
Nasopharynx	0.5	1.1	0.6	0.8	0.6	160	0.7
Tonsil	2.2	2.2	2.3	2.1	2.1	489	2.2
Oropharynx	0.9	0.7	0.9	0.5	0.6	155	0.7
Hypopharynx	1.5	1.1	1.0	1.2	1.1	247	1.2
<b>Digestive System</b>	119.8	118.9	112.4	112.6	108.7	22,841	114.4
Esophagus	9.4	8.2	8.8	8.8	8.1	1,765	8.7
Stomach	13.0	12.9	11.9	11.9	11.1	2,396	12.1
Small Intestine	2.7	2.7	2.5	2.4	2.8	541	2.6
Colon and Rectum	65.1	65.5	58.8	57.8	55.8	11,962	60.5
Colon excluding Rectum	44.8	46.1	41.4	40.2	38.6	8,219	42.2
Rectum and Rectosigmoid Junction	20.4	19.4	17.4	17.6	17.1	3,743	18.3
Anus, Anal Canal and Anorectum	1.0	1.1	1.5	1.1	1.6	270	1.3
Liver and Intrahepatic Bile Duct	9.8	10.3	9.7	10.1	10.1	2,110	10.0
Liver	9.3	9.6	9.0	9.3	9.6	1,983	9.4
Intrahepatic Bile Duct	0.5	0.7	0.6	0.8	0.5	127	0.6
Gallbladder	0.9	0.8	1.3	0.9	1.1	197	1.0
Other Biliary	2.5	1.9	2.1	2.3	2.5	444	2.3
Pancreas	14.5	14.2	14.8	16.0	14.6	2,940	14.8
<b>Respiratory System</b>	83.7	88.0	87.6	84.7	79.3	16,754	84.6
Larynx	6.8	6.8	7.9	6.3	5.8	1,390	6.7
Lung and Bronchus	75.9	80.0	78.6	77.3	72.0	15,117	76.7
<b>Bones and Joints</b>	1.2	1.0	1.3	1.4	1.0	247	1.2
<b>Soft Tissue (Including Heart)</b>	3.7	4.1	3.7	4.6	4.2	825	4.1
<b>Skin (Excluding Basal and Squamous)</b>	29.8	27.2	29.5	30.1	29.5	5,929	29.2
Melanoma of the Skin	27.8	25.1	27.2	27.8	27.5	5,515	27.1

Rates are per 100,000 population and age-adjusted to the 2000 U.S. population standard.

- Counts and rates are suppressed when fewer than 5 cases to ensure confidentiality and statistical reliability.

**Table 1 (continued). Age-adjusted Incidence Rates, Males All Races Combined**

Cancer Site	Rates					Cases	Rates
	2004	2005	2006	2007	2008	2004-2008	
<b>Breast</b>	1.8	2.0	1.4	2.1	1.6	347	1.8
<b>Male Genital System</b>	167.2	169.3	188.8	192.6	168.5	36,548	177.4
Prostate	159.9	163.6	182.2	185.8	162.2	35,179	170.8
Testis	6.3	4.9	5.7	5.6	5.2	1,171	5.5
Penis	0.7	0.6	0.8	0.9	0.8	152	0.8
<b>Urinary System</b>	71.4	69.5	71.8	71.5	66.5	13,785	70.1
Urinary Bladder (Including in situ)	49.3	46.8	48.0	46.7	43.0	8,982	46.7
Kidney and Renal Pelvis	21.0	21.1	21.9	23.1	21.6	4,498	21.7
Ureter	0.8	1.1	1.0	1.1	0.9	186	1.0
<b>Eye and Orbit</b>	1.2	0.8	1.1	1.0	0.9	205	1.0
<b>Brain and Other Nervous System</b>	8.1	9.0	9.0	8.1	8.3	1,760	8.5
Brain	7.6	8.4	8.5	7.5	7.6	1,642	7.9
<b>Endocrine System</b>	7.3	7.7	8.3	8.5	9.2	1,756	8.2
Thyroid	6.5	6.5	7.4	7.4	8.1	1,543	7.2
<b>Lymphomas</b>	29.3	29.7	29.9	28.4	28.5	5,922	29.1
Hodgkin Lymphoma	3.5	3.8	3.6	3.3	3.5	741	3.5
Non-Hodgkin Lymphoma	25.9	25.9	26.3	25.1	25.0	5,181	25.6
<b>Myelomas</b>	8.3	7.8	8.0	8.4	7.7	1,614	8.0
<b>Leukemias</b>	18.5	16.9	17.1	17.3	15.9	3,422	17.2
Lymphocytic Leukemia	10.2	8.8	9.1	8.9	8.2	1,815	9.0
Acute Lymphocytic Leukemia	2.1	2.0	2.0	2.0	1.6	406	2.0
Chronic Lymphocytic Leukemia	7.3	6.1	6.2	6.2	5.8	1,255	6.3
Myeloid and Monocytic Leukemia	7.5	7.3	7.2	7.5	7.1	1,455	7.3
Acute Myeloid Leukemia	5.0	4.9	5.0	4.7	4.3	940	4.8
Acute Monocytic Leukemia	0.3	0.3	0.4	0.5	0.4	73	0.4
Chronic Myeloid Leukemia	1.9	2.0	1.6	2.1	2.1	394	1.9
Other Leukemia	0.8	0.8	0.8	0.9	0.6	152	0.8
<b>Mesothelioma</b>	3.1	3.3	2.4	2.8	2.8	535	2.9
<b>Kaposi Sarcoma</b>	1.1	1.2	0.8	0.9	0.6	192	0.9
<b>Ill-Defined &amp; Unspecified Sites</b>	11.8	11.2	12.1	11.1	10.9	2,215	11.4

Rates are per 100,000 population and age-adjusted to the 2000 U.S. population standard.

- Counts and rates are suppressed when fewer than 5 cases to ensure confidentiality and statistical reliability.

**Table 2. Age-adjusted Incidence Rates, Females All Races Combined**

Cancer Site	Rates					Cases 2004-2008	Rates
	2004	2005	2006	2007	2008 Prelim.		
<b>All Sites</b>	451.4	447.1	452.2	448.1	440.5	115,493	447.8
<b>Oral Cavity and Pharynx</b>	6.4	5.6	6.4	5.5	5.9	1,545	6.0
Lip	0.3	0.1	0.3	0.2	0.3	68	0.2
Tongue	1.7	1.7	1.9	1.6	1.7	449	1.7
Salivary Gland	1.2	1.1	1.0	1.1	1.2	278	1.1
Floor of Mouth	0.5	0.3	0.4	0.2	0.3	90	0.3
Gum and Other Mouth	1.2	1.2	1.3	1.1	1.1	318	1.2
Nasopharynx	0.3	0.3	0.3	0.3	0.3	75	0.3
Tonsil	0.6	0.4	0.6	0.5	0.5	126	0.5
Oropharynx	0.3	0.1	0.2	0.2	0.3	59	0.2
Hypopharynx	0.3	0.2	0.3	0.2	0.1	60	0.2
<b>Digestive System</b>	79.0	78.4	76.1	74.1	71.1	20,473	75.7
Esophagus	2.0	1.9	2.3	1.9	2.1	551	2.0
Stomach	6.7	5.9	5.6	6.2	5.9	1,647	6.1
Small Intestine	1.8	2.1	1.9	1.4	2.0	485	1.8
Colon and Rectum	46.9	47.7	45.2	42.4	39.9	12,028	44.4
Colon excluding Rectum	34.9	35.7	33.1	31.3	30.1	9,017	33.0
Rectum and Rectosigmoid Junction	12.0	12.0	12.1	11.0	9.9	3,011	11.4
Anus, Anal Canal and Anorectum	1.8	1.9	1.6	1.7	2.0	460	1.8
Liver and Intrahepatic Bile Duct	3.3	2.9	3.4	3.8	3.2	885	3.3
Liver	2.7	2.4	2.7	3.1	2.7	728	2.7
Intrahepatic Bile Duct	0.6	0.5	0.7	0.7	0.4	157	0.6
Gallbladder	1.9	1.6	1.6	1.9	1.6	475	1.7
Other Biliary	1.5	2.1	1.8	1.6	1.2	451	1.6
Pancreas	11.6	10.8	11.2	11.0	11.5	3,052	11.2
<b>Respiratory System</b>	57.3	59.3	59.6	59.5	58.7	15,460	58.9
Larynx	1.5	1.2	1.4	1.7	1.4	368	1.4
Lung and Bronchus	55.1	57.3	57.4	57.2	56.6	14,898	56.7
<b>Bones and Joints</b>	1.2	0.9	0.8	0.7	1.0	205	0.9
<b>Soft Tissue (Including Heart)</b>	3.3	3.0	2.9	2.7	2.6	721	2.9
<b>Skin (Excluding Basal and Squamous)</b>	17.5	19.6	19.6	20.2	17.7	4,698	19.0
Melanoma of the Skin	16.3	18.5	18.6	19.0	16.5	4,394	17.8
<b>Breast (Invasive)</b>	131.9	127.8	128.4	130.4	129.8	32,993	129.7
In situ (not included in All Sites)	36.5	35.3	39.5	39.1	41.3	9,593	38.4

Rates are per 100,000 population and age-adjusted to the 2000 U.S. population standard.

- Counts and rates are suppressed when fewer than 5 cases to ensure confidentiality and statistical reliability.

**Table 2 (continued). Age-adjusted Incidence Rates, Females All Races Combined**

Cancer Site	Rates					Cases 2004-2008	Rates
	2004	2005	2006	2007	2008 Prelim.		
<b>Female Genital System</b>	54.3	55.8	58.9	57.3	54.8	14,342	56.2
Cervix Uteri	9.5	8.6	9.6	9.4	8.0	2,131	9.0
Corpus and Uterus, NOS	27.6	29.7	30.2	30.3	29.3	7,619	29.4
Corpus Uteri	26.7	28.8	29.3	29.7	28.5	7,395	28.6
Uterus, NOS	1.0	0.9	1.0	0.6	0.8	224	0.8
Ovary	13.7	14.1	15.0	13.5	13.3	3,573	13.9
Vagina	0.6	0.8	0.8	0.7	0.7	189	0.7
Vulva	2.1	2.1	2.5	2.4	2.5	619	2.3
<b>Urinary System</b>	25.2	23.5	23.2	22.9	23.0	6,231	23.6
Urinary Bladder (Including in situ)	13.7	12.0	12.2	11.7	11.5	3,303	12.2
Kidney and Renal Pelvis	11.0	11.0	10.4	10.5	10.9	2,762	10.8
Ureter	0.5	0.4	0.4	0.6	0.4	122	0.4
<b>Eye and Orbit</b>	0.6	0.7	0.8	0.7	0.4	153	0.6
<b>Brain and Other Nervous System</b>	6.8	5.8	5.5	6.2	5.8	1,470	6.0
Brain	6.2	5.2	5.1	5.5	5.3	1,327	5.4
<b>Endocrine System</b>	20.0	20.5	22.5	22.8	24.9	5,143	22.1
Thyroid	19.2	19.7	22.0	22.0	24.2	4,977	21.4
<b>Lymphomas</b>	21.1	20.8	21.0	20.3	21.0	5,295	20.8
Hodgkin Lymphoma	3.0	3.5	2.9	3.0	3.4	697	3.2
Non-Hodgkin Lymphoma	18.1	17.3	18.0	17.4	17.6	4,598	17.7
<b>Myelomas</b>	4.9	5.7	5.3	5.2	4.8	1,384	5.2
<b>Leukemias</b>	10.7	9.7	11.0	10.4	9.6	2,639	10.3
Lymphocytic Leukemia	5.4	5.1	5.3	5.0	3.8	1,256	4.9
Acute Lymphocytic Leukemia	1.4	1.2	1.5	1.8	1.2	308	1.4
Chronic Lymphocytic Leukemia	3.6	3.5	3.6	3.0	2.3	870	3.2
Myeloid and Monocytic Leukemia	4.8	3.9	5.2	4.9	5.2	1,230	4.8
Acute Myeloid Leukemia	3.4	2.8	3.3	3.2	3.6	839	3.3
Acute Monocytic Leukemia	0.1	0.1	0.2	0.3	0.2	50	0.2
Chronic Myeloid Leukemia	1.2	0.9	1.5	1.3	1.2	304	1.2
Other Leukemia	0.5	0.7	0.5	0.5	0.6	153	0.6
<b>Mesothelioma</b>	0.5	0.6	0.7	0.6	0.8	171	0.6
<b>Kaposi Sarcoma</b>	0.1	0.1	0.1	0.2	0.2	41	0.1
<b>Ill-Defined &amp; Unspecified Sites</b>	10.5	9.2	9.2	8.3	8.4	2,529	9.1

Rates are per 100,000 population and age-adjusted to the 2000 U.S. population standard.

- Counts and rates are suppressed when fewer than 5 cases to ensure confidentiality and statistical reliability.

**Table 3. Age-adjusted Incidence Rates, White Males**

Cancer Site	Rates					Total 2004-2008	Rates
	2004	2005	2006	2007	2008		
<b>All Sites</b>	576.4	581.3	601.9	600.8	565.9	99,210	585.2
<b>Oral Cavity and Pharynx</b>	14.0	14.5	15.6	15.2	14.1	2,604	14.7
Lip	0.5	0.6	0.4	0.8	0.5	94	0.6
Tongue	4.6	4.5	5.5	5.2	4.6	874	4.9
Salivary Gland	1.5	1.9	2.1	2.1	2.0	316	1.9
Floor of Mouth	0.7	0.9	0.7	0.9	0.7	140	0.8
Gum and Other Mouth	1.9	1.6	1.9	1.6	1.6	297	1.7
Nasopharynx	0.4	0.7	0.3	0.7	0.5	90	0.5
Tonsil	2.2	2.4	2.5	2.1	2.2	424	2.3
Oropharynx	0.9	0.7	1.0	0.5	0.6	134	0.7
Hypopharynx	1.3	1.1	0.8	1.0	1.0	186	1.0
<b>Digestive System</b>	117.8	117.7	111.6	111.0	108.5	19,093	113.3
Esophagus	9.4	8.2	9.0	9.1	8.3	1,509	8.8
Stomach	12.0	12.0	11.1	10.8	10.5	1,883	11.3
Small Intestine	2.6	2.5	2.5	2.2	2.9	438	2.5
Colon and Rectum	65.5	65.8	59.4	57.8	56.5	10,195	61.0
Colon excluding Rectum	45.2	46.4	41.8	40.6	39.2	7,059	42.6
Rectum and Rectosigmoid Junction	20.3	19.4	17.7	17.2	17.3	3,136	18.3
Anus, Anal Canal and Anorectum	1.0	1.1	1.5	1.0	1.6	219	1.2
Liver and Intrahepatic Bile Duct	8.6	10.0	8.9	9.5	9.2	1,620	9.2
Liver	8.0	9.3	8.2	8.8	8.7	1,514	8.6
Intrahepatic Bile Duct	0.5	0.7	0.7	0.7	0.4	106	0.6
Gallbladder	0.9	0.8	1.1	0.9	1.0	154	0.9
Other Biliary	2.6	2.0	2.2	2.2	2.6	389	2.3
Pancreas	14.5	14.1	15.0	16.1	14.9	2,508	14.9
<b>Respiratory System</b>	83.6	88.0	89.0	85.0	80.3	14,299	85.2
Larynx	6.5	6.8	7.7	6.0	5.6	1,136	6.5
Lung and Bronchus	76.1	80.1	80.1	77.8	73.1	12,960	77.4
<b>Bones and Joints</b>	1.3	1.1	1.3	1.5	1.2	204	1.3
<b>Soft Tissue (Including Heart)</b>	3.6	4.2	3.7	4.9	4.5	691	4.2
<b>Skin (Excluding Basal and Squamous)</b>	33.7	31.6	32.7	33.2	33.6	5,591	33.0
Melanoma of the Skin	31.5	29.4	30.2	30.9	31.4	5,223	30.7

Rates are per 100,000 population and age-adjusted to the 2000 U.S. population standard.

- Counts and rates are suppressed when fewer than 5 cases to ensure confidentiality and statistical reliability.

**Table 3 (continued). Age-adjusted Incidence Rates, White Males**

Cancer Site	Rates					Cases	Rates
	2004	2005	2006	2007	2008	2004-2008	
<b>Breast</b>	1.8	2.0	1.3	2.1	1.5	287	1.7
<b>Male Genital System</b>	155.1	159.1	179.6	182.2	163.2	28,998	167.9
Prostate	146.6	152.3	171.6	173.8	155.7	27,736	160.1
Testis	7.6	5.9	7.0	7.2	6.5	1,092	6.8
Penis	0.7	0.7	0.8	0.9	0.8	133	0.8
<b>Urinary System</b>	75.2	73.5	75.1	75.3	70.7	12,348	73.9
Urinary Bladder (Including in situ)	52.2	50.2	51.0	49.4	46.3	8,200	49.8
Kidney and Renal Pelvis	21.8	21.8	22.1	24.1	22.4	3,873	22.4
Ureter	0.9	1.2	1.1	1.2	1.0	172	1.1
<b>Eye and Orbit</b>	1.3	0.9	1.3	1.0	1.0	188	1.1
<b>Brain and Other Nervous System</b>	9.0	9.7	9.7	8.7	9.1	1,548	9.2
Brain	8.5	9.1	9.0	8.2	8.4	1,452	8.6
<b>Endocrine System</b>	7.7	7.7	8.9	9.4	9.9	1,500	8.7
Thyroid	6.9	6.7	8.0	8.3	8.7	1,335	7.7
<b>Lymphomas</b>	30.2	30.4	30.9	29.9	30.0	5,092	30.3
Hodgkin Lymphoma	3.5	4.0	3.6	3.4	3.6	593	3.6
Non-Hodgkin Lymphoma	26.7	26.4	27.4	26.5	26.3	4,499	26.7
<b>Myelomas</b>	7.6	7.3	7.6	7.7	7.2	1,265	7.5
<b>Leukemias</b>	18.8	17.9	18.1	18.3	16.4	2,974	17.9
Lymphocytic Leukemia	10.5	9.3	9.9	9.2	8.7	1,583	9.5
Acute Lymphocytic Leukemia	2.3	2.1	2.2	2.1	1.8	335	2.1
Chronic Lymphocytic Leukemia	7.5	6.4	6.7	6.3	6.1	1,111	6.6
Myeloid and Monocytic Leukemia	7.5	7.8	7.4	8.1	7.2	1,265	7.6
Acute Myeloid Leukemia	5.2	5.2	5.3	5.0	4.5	835	5.0
Acute Monocytic Leukemia	0.3	0.3	0.4	0.6	0.4	68	0.4
Chronic Myeloid Leukemia	1.7	2.0	1.5	2.2	2.1	323	1.9
Other Leukemia	0.8	0.8	0.8	1.0	0.5	126	0.8
<b>Mesothelioma</b>	3.3	3.5	2.6	3.1	3.2	504	3.1
<b>Kaposi Sarcoma</b>	0.9	0.9	0.6	0.8	0.6	128	0.8
<b>Ill-Defined &amp; Unspecified Sites</b>	11.6	11.1	12.2	11.5	11.0	1,896	11.5

Rates are per 100,000 population and age-adjusted to the 2000 U.S. population standard.

- Counts and rates are suppressed when fewer than 5 cases to ensure confidentiality and statistical reliability.

**Table 4. Age-adjusted Incidence Rates, White Females**

Cancer Site	Rates					Cases 2004-2008	Rates
	2004	2005	2006	2007	2008 Prelim.		
<b>All Sites</b>	465.7	461.9	463.4	461.5	456.2	98,201	461.7
<b>Oral Cavity and Pharynx</b>	6.7	5.6	6.3	5.5	6.3	1,309	6.1
Lip	0.3	0.2	0.4	0.2	0.3	62	0.3
Tongue	1.8	1.8	2.0	1.7	2.0	394	1.8
Salivary Gland	1.3	1.0	1.0	1.1	1.1	223	1.1
Floor of Mouth	0.5	0.4	0.3	0.2	0.4	79	0.4
Gum and Other Mouth	1.3	1.2	1.4	1.0	1.3	274	1.2
Nasopharynx	0.2	0.3	0.3	0.3	0.2	49	0.3
Tonsil	0.7	0.4	0.6	0.5	0.5	110	0.5
Oropharynx	0.3	-	0.2	0.2	0.3	47	0.2
Hypopharynx	0.3	0.3	0.2	0.2	0.1	51	0.2
<b>Digestive System</b>	77.4	77.2	73.9	72.1	69.7	16,995	74.0
Esophagus	1.9	1.7	2.2	2.0	1.8	440	1.9
Stomach	6.2	5.1	4.9	5.6	5.3	1,254	5.4
Small Intestine	1.8	2.0	1.8	1.3	1.9	389	1.8
Colon and Rectum	46.7	47.6	44.2	41.6	39.6	10,109	43.9
Colon excluding Rectum	34.5	35.4	32.6	30.3	29.9	7,588	32.5
Rectum and Rectosigmoid Junction	12.2	12.2	11.6	11.3	9.7	2,521	11.4
Anus, Anal Canal and Anorectum	1.9	1.9	1.6	1.9	2.2	398	1.9
Liver and Intrahepatic Bile Duct	2.9	2.8	3.3	3.2	3.0	692	3.1
Liver	2.3	2.2	2.6	2.5	2.6	556	2.5
Intrahepatic Bile Duct	0.6	0.6	0.8	0.7	0.3	136	0.6
Gallbladder	1.7	1.5	1.5	1.7	1.6	382	1.6
Other Biliary	1.3	2.1	1.8	1.6	1.2	378	1.6
Pancreas	11.5	10.8	11.1	11.0	11.4	2,582	11.1
<b>Respiratory System</b>	58.6	61.9	62.2	62.3	61.5	13,493	61.2
Larynx	1.5	1.2	1.4	1.6	1.4	306	1.4
Lung and Bronchus	56.3	59.8	60.0	60.0	59.3	13,021	59.0
<b>Bones and Joints</b>	1.2	1.0	0.8	0.8	1.1	168	1.0
<b>Soft Tissue (Including Heart)</b>	3.2	3.2	2.8	2.8	2.7	595	3.0
<b>Skin (Excluding Basal and Squamous)</b>	20.6	23.7	22.4	23.1	20.6	4,387	22.1
Melanoma of the Skin	19.4	22.6	21.2	21.7	19.5	4,130	20.9
<b>Breast (Invasive)</b>	138.0	131.9	132.1	134.2	133.5	27,821	133.9
In situ (not included in All Sites)	38.6	36.3	40.9	40.5	43.3	8,039	39.9

**Table 4 (continued). Age-adjusted Incidence Rates, White Females**

Cancer Site	Rates					Cases 2004-2008	Rates
	2004	2005	2006	2007	2008 Prelim.		
<b>Female Genital System</b>	56.1	57.7	60.5	58.8	56.5	12,074	57.9
Cervix Uteri	9.1	8.1	9.0	8.7	7.9	1,584	8.6
Corpus and Uterus, NOS	29.3	31.1	31.8	31.5	30.5	6,553	30.8
Corpus Uteri	28.4	30.3	30.8	31.0	29.9	6,382	30.1
Uterus, NOS	0.9	0.8	0.9	0.5	0.7	171	0.8
Ovary	14.4	15.2	15.6	14.2	13.8	3,079	14.6
Vagina	0.6	0.6	0.7	0.7	0.5	140	0.6
Vulva	2.1	2.2	2.6	2.6	2.7	547	2.4
<b>Urinary System</b>	26.6	24.6	23.5	23.9	24.2	5,440	24.6
Urinary Bladder (Including in situ)	14.4	12.8	12.4	12.3	12.2	2,936	12.8
Kidney and Renal Pelvis	11.6	11.3	10.6	10.8	11.3	2,361	11.1
Ureter	0.5	0.5	0.4	0.6	0.5	110	0.5
<b>Eye and Orbit</b>	0.7	0.8	0.8	0.7	0.5	143	0.7
<b>Brain and Other Nervous System</b>	7.1	6.3	6.0	6.9	6.3	1,282	6.5
Brain	6.7	5.7	5.6	6.1	5.9	1,178	6.0
<b>Endocrine System</b>	21.8	21.7	24.1	24.4	26.7	4,288	23.7
Thyroid	21.1	20.8	23.5	23.7	26.2	4,162	23.0
<b>Lymphomas</b>	21.9	21.6	22.2	21.6	22.8	4,609	22.0
Hodgkin Lymphoma	3.3	3.8	3.2	3.4	3.9	595	3.5
Non-Hodgkin Lymphoma	18.6	17.8	19.0	18.2	18.9	4,014	18.5
<b>Myelomas</b>	4.1	4.8	4.5	4.6	4.4	1,010	4.5
<b>Leukemias</b>	10.8	10.0	11.2	10.9	10.1	2,259	10.6
Lymphocytic Leukemia	5.4	5.5	5.4	5.5	4.2	1,104	5.2
Acute Lymphocytic Leukemia	1.4	1.3	1.5	2.0	1.4	253	1.5
Chronic Lymphocytic Leukemia	3.6	3.8	3.7	3.2	2.5	781	3.4
Myeloid and Monocytic Leukemia	4.8	3.8	5.3	5.0	5.3	1,025	4.8
Acute Myeloid Leukemia	3.4	2.8	3.3	3.3	3.7	702	3.3
Acute Monocytic Leukemia	0.2	0.1	0.3	0.3	0.3	49	0.2
Chronic Myeloid Leukemia	1.2	0.7	1.5	1.2	1.2	242	1.2
Other Leukemia	0.6	0.6	0.5	0.5	0.6	130	0.6
<b>Mesothelioma</b>	0.5	0.6	0.8	0.6	0.9	157	0.7
<b>Kaposi Sarcoma</b>	0.1	0.1	0.1	0.1	-	28	0.1
<b>Ill-Defined &amp; Unspecified Sites</b>	10.4	9.1	9.2	8.1	8.4	2,143	9.0

Rates are per 100,000 population and age-adjusted to the 2000 U.S. population standard.

- Counts and rates are suppressed when fewer than 5 cases to ensure confidentiality and statistical reliability.

**Table 5. Age-adjusted Incidence Rates, Black Males**

Cancer Site	Rates					Cases 2004-2008	Rates
	2004	2005	2006	2007	2008		
<b>All Sites</b>	655.8	622.7	603.0	589.4	560.3	12,802	605.3
					Prelim.		
<b>Oral Cavity and Pharynx</b>	22.4	12.9	14.6	14.0	11.9	353	15.1
Lip	-	-	-	-	-	-	-
Tongue	6.3	3.2	5.3	3.2	3.8	99	4.3
Salivary Gland	2.6	0.8	-	-	-	26	1.0
Floor of Mouth	1.1	-	1.1	1.5	-	21	0.9
Gum and Other Mouth	1.2	1.9	1.6	1.6	1.9	39	1.7
Nasopharynx	1.4	1.7	1.0	0.9	1.6	32	1.3
Tonsil	3.9	1.7	2.1	2.4	1.6	58	2.3
Oropharynx	1.4	-	-	-	-	18	0.8
Hypopharynx	3.8	1.6	2.2	2.9	1.0	51	2.3
<b>Digestive System</b>	132.6	128.1	126.2	128.5	121.6	2,601	127.3
Esophagus	10.6	11.3	9.6	9.8	9.0	209	10.1
Stomach	17.5	17.0	17.2	18.5	16.0	325	17.2
Small Intestine	3.6	3.9	2.1	4.4	3.1	73	3.4
Colon and Rectum	67.6	67.8	61.3	59.1	55.6	1,236	62.1
Colon excluding Rectum	48.3	50.9	43.8	42.4	41.3	874	45.2
Rectum and Rectosigmoid Junction	19.3	16.9	17.4	16.7	14.2	362	16.8
Anus, Anal Canal and Anorectum	1.5	1.5	1.4	1.9	2.0	44	1.7
Liver and Intrahepatic Bile Duct	14.1	7.6	13.1	10.9	16.5	302	12.5
Liver	13.9	6.9	12.6	9.7	15.5	287	11.8
Intrahepatic Bile Duct	-	-	-	1.2	-	15	0.7
Gallbladder	-	-	2.4	-	1.7	28	1.4
Other Biliary	1.7	2.1	1.5	3.6	1.4	38	2.1
Pancreas	14.2	15.3	16.6	17.6	15.1	322	15.8
<b>Respiratory System</b>	101.4	100.8	93.8	101.7	86.8	1,967	96.8
Larynx	11.7	8.9	10.3	9.8	8.8	215	9.9
Lung and Bronchus	88.6	90.5	82.7	90.6	76.9	1,729	85.8
<b>Bones and Joints</b>	1.0	1.3	1.1	1.3	-	32	1.1
<b>Soft Tissue (Including Heart)</b>	5.1	4.2	4.3	3.0	2.6	94	3.8
<b>Skin (Excluding Basal and Squamous)</b>	2.1	3.2	2.0	2.1	2.2	51	2.3
Melanoma of the Skin	1.7	1.5	1.3	-	-	24	1.3

Rates are per 100,000 population and age-adjusted to the 2000 U.S. population standard.

- Counts and rates are suppressed when fewer than 5 cases to ensure confidentiality and statistical reliability.

**Table 5 (continued). Age-adjusted Incidence Rates, Black Males**

Cancer Site	Rates					Cases 2004-2008	Rates
	2004	2005	2006	2007	2008 Prelim.		
<b>Breast</b>	2.2	1.8	2.7	2.9	1.7	48	2.3
<b>Male Genital System</b>	259.4	243.7	246.7	233.1	218.2	5,141	239.7
Prostate	257.4	242.0	244.7	232.2	216.3	5,095	238.0
Testis	1.6	0.9	1.0	-	0.8	30	1.0
Penis	-	-	-	-	1.0	12	0.5
<b>Urinary System</b>	43.0	45.5	47.2	41.4	42.7	885	43.9
Urinary Bladder (Including in situ)	24.6	22.8	21.2	20.8	21.1	400	22.1
Kidney and Renal Pelvis	17.6	21.7	24.7	20.2	20.8	467	21.0
Ureter	-	-	-	-	-	6	0.3
<b>Eye and Orbit</b>	-	-	-	-	-	7	0.2
<b>Brain and Other Nervous System</b>	3.8	5.6	5.6	4.2	5.6	121	5.0
Brain	3.5	5.4	5.3	3.6	5.1	111	4.6
<b>Endocrine System</b>	3.3	6.9	4.5	3.6	5.5	115	4.8
Thyroid	3.0	4.4	3.8	3.1	4.5	89	3.8
<b>Lymphomas</b>	25.3	24.1	19.4	15.5	21.4	528	21.1
Hodgkin Lymphoma	4.7	2.8	4.0	2.5	4.0	107	3.6
Non-Hodgkin Lymphoma	20.6	21.3	15.4	13.0	17.4	421	17.5
<b>Myelomas</b>	17.6	12.5	10.3	15.4	12.7	275	13.7
<b>Leukemias</b>	16.5	12.5	9.8	10.2	11.9	258	12.1
Lymphocytic Leukemia	7.7	6.5	4.0	5.3	4.5	116	5.6
Acute Lymphocytic Leukemia	1.1	1.5	1.5	0.8	0.7	35	1.1
Chronic Lymphocytic Leukemia	4.9	4.6	2.6	4.0	3.1	68	3.8
Myeloid and Monocytic Leukemia	8.2	5.1	4.9	3.9	6.3	124	5.7
Acute Myeloid Leukemia	3.7	2.8	2.7	2.5	2.9	69	2.9
Acute Monocytic Leukemia	-	-	-	-	-	-	-
Chronic Myeloid Leukemia	3.6	2.3	1.6	-	2.4	45	2.2
Other Leukemia	-	-	-	-	-	18	0.9
<b>Mesothelioma</b>	1.3	2.3	-	-	-	22	1.3
<b>Kaposi Sarcoma</b>	2.9	2.9	1.5	1.2	-	52	1.8
<b>Ill-Defined &amp; Unspecified Sites</b>	15.3	14.1	11.9	9.9	13.4	252	12.9

Rates are per 100,000 population and age-adjusted to the 2000 U.S. population standard.

- Counts and rates are suppressed when fewer than 5 cases to ensure confidentiality and statistical reliability.

**Table 6. Age-adjusted Incidence Rates, Black Females**

Cancer Site	Rates					Cases 2004-2008	Rates
	2004	2005	2006	2007	2008		
<b>All Sites</b>	402.0	396.9	399.6	394.2	382.7	12,054	394.9
					Prelim.		
<b>Oral Cavity and Pharynx</b>	4.9	4.5	5.3	5.6	3.9	154	4.8
Lip	-	-	-	-	-	-	-
Tongue	1.0	-	1.7	1.1	0.9	33	1.1
Salivary Gland	1.0	1.6	0.9	1.5	1.4	42	1.3
Floor of Mouth	-	-	-	-	-	6	0.2
Gum and Other Mouth	-	1.0	0.8	1.6	-	26	0.9
Nasopharynx	-	-	-	0.7	-	15	0.5
Tonsil	-	-	-	-	-	12	0.4
Oropharynx	-	-	-	-	-	11	0.4
Hypopharynx	-	-	-	-	-	6	0.2
<b>Digestive System</b>	89.7	90.7	92.2	92.6	84.3	2,631	89.9
Esophagus	2.9	3.6	2.9	2.2	3.6	93	3
Stomach	9.0	11.1	9.7	8.9	8.2	267	9.4
Small Intestine	1.6	2.4	3.2	2.4	3.4	78	2.6
Colon and Rectum	50.8	50.9	53.3	50.9	43.9	1,464	49.9
Colon excluding Rectum	40.3	39.9	38.4	40.1	32.6	1,113	38.2
Rectum and Rectosigmoid Junction	10.5	10.9	14.8	10.7	11.4	351	11.7
Anus, Anal Canal and Anorectum	1.6	2.4	2.2	1.3	1.5	55	1.8
Liver and Intrahepatic Bile Duct	4.7	2.7	3.0	6.6	4.1	129	4.3
Liver	4.0	2.4	2.7	5.7	3.0	108	3.5
Intrahepatic Bile Duct	-	-	-	1.0	1.2	21	0.7
Gallbladder	2.3	2.0	2.4	3.5	1.9	71	2.4
Other Biliary	1.5	2.5	1.0	1.2	1.3	45	1.5
Pancreas	13.8	11.7	13.4	13.9	14.1	382	13.4
<b>Respiratory System</b>	59.5	53.7	53.1	51.1	53.4	1,608	54.1
Larynx	2.0	1.0	1.4	2.5	1.8	54	1.7
Lung and Bronchus	57.0	52.0	50.8	48.2	51.4	1,539	51.8
<b>Bones and Joints</b>	1.1	0.9	-	-	-	23	0.7
<b>Soft Tissue (Including Heart)</b>	3.3	2.1	3.1	2.5	3.1	91	2.8
<b>Skin (Excluding Basal and Squamous)</b>	2.5	2.5	2.2	1.6	1.9	67	2.1
Melanoma of the Skin	1.4	0.8	1.4	0.9	0.9	33	1.1
<b>Breast (Invasive)</b>	106.3	110.0	110.5	117.4	115.3	3,532	111.9
In situ (not included in All Sites)	26.4	27.1	26.3	30.2	29.2	893	27.9

Rates are per 100,000 population and age-adjusted to the 2000 U.S. population standard.

- Counts and rates are suppressed when fewer than 5 cases to ensure confidentiality and statistical reliability.

**Table 6 (continued). Age-adjusted Incidence Rates, Black Females**

Cancer Site	Rates					Cases	Rates
	2004	2005	2006	2007	2008	2004-2008	
					Prelim.		
<b>Female Genital System</b>	47.8	51.1	50.7	50.5	48.7	1,553	49.8
Cervix Uteri	14.2	12.9	12.5	13.3	10.0	406	12.6
Corpus and Uterus, NOS	19.4	24.2	22.6	24.1	23.8	710	22.9
Corpus Uteri	17.9	22.2	21.2	22.9	22.7	666	21.4
Uterus, NOS	1.6	2.0	1.4	1.2	1.1	44	1.4
Ovary	10.6	9.9	12.3	9.8	10.7	323	10.7
Vagina	0.8	1.5	1.3	-	1.7	36	1.2
Vulva	1.4	1.5	1.5	1.9	1.5	49	1.6
<b>Urinary System</b>	21.4	19.1	21.3	15.7	18.1	562	19.1
Urinary Bladder (Including in situ)	11.0	7.1	10.0	6.4	7.2	233	8.3
Kidney and Renal Pelvis	9.9	11.1	10.6	8.8	10.3	311	10.1
Ureter	-	-	-	-	-	9	0.3
<b>Eye and Orbit</b>	-	-	-	-	-	-	-
<b>Brain and Other Nervous System</b>	4.3	2.3	3.5	3.1	2.6	101	3.1
Brain	2.9	1.9	2.5	2.3	2.1	74	2.3
<b>Endocrine System</b>	10.6	10.9	12.0	12.3	13.3	387	11.8
Thyroid	9.7	10.2	11.3	11.2	12.1	357	10.9
<b>Lymphomas</b>	17.9	16.7	13.3	14.2	12.3	466	14.9
Hodgkin Lymphoma	2.7	2.9	1.9	1.7	2.3	76	2.3
Non-Hodgkin Lymphoma	15.1	13.8	11.5	12.5	10.0	390	12.6
<b>Myelomas</b>	11.9	12.9	10.6	8.8	8.2	305	10.5
<b>Leukemias</b>	8.4	7.8	9.3	6.6	6.2	234	7.6
Lymphocytic Leukemia	3.5	2.7	4.0	2.1	1.3	84	2.7
Acute Lymphocytic Leukemia	1.2	0.9	1.4	0.7	0.9	34	1
Chronic Lymphocytic Leukemia	2.1	1.7	2.5	1.4	-	47	1.6
Myeloid and Monocytic Leukemia	4.5	3.7	4.8	4.2	4.5	133	4.3
Acute Myeloid Leukemia	3.7	2.2	3.3	2.7	3.6	93	3.1
Acute Monocytic Leukemia	-	-	-	-	-	-	-
Chronic Myeloid Leukemia	0.9	1.4	1.3	1.4	0.9	38	1.2
Other Leukemia	-	1.5	-	-	-	17	0.6
<b>Mesothelioma</b>	-	-	-	-	-	11	0.4
<b>Kaposi Sarcoma</b>	-	-	-	-	-	10	0.3
<b>Ill-Defined &amp; Unspecified Sites</b>	11.8	10.9	10.9	11.0	10.1	315	10.9

Rates are per 100,000 population and age-adjusted to the 2000 U.S. population standard.

- Counts and rates are suppressed when fewer than 5 cases to ensure confidentiality and statistical reliability.

**Table 7. Age-adjusted Incidence Rates, Hispanic Males**

Cancer Site	Rates					Cases 2004-2008	Rates
	2004	2005	2006	2007	2008		
<b>All Sites</b>	544.8	491.7	475.6	434.5	426.2	8,544	470.7
					Prelim.		
<b>Oral Cavity and Pharynx</b>	15.3	13.0	11.5	11.7	8.2	234	11.7
Lip	1.5	-	-	1.6	-	14	0.8
Tongue	5.0	3.9	3.2	3.0	2.7	70	3.5
Salivary Gland	-	-	1.7	1.6	1.8	24	1.2
Floor of Mouth	-	-	-	-	-	11	0.4
Gum and Other Mouth	1.7	-	-	1.1	-	23	1.1
Nasopharynx	-	-	-	1.2	-	16	0.8
Tonsil	1.4	2.5	2.0	-	0.9	33	1.4
Oropharynx	1.8	1.8	1.1	-	-	20	1.0
Hypopharynx	-	-	-	-	-	16	1.0
<b>Digestive System</b>	138.9	109.9	110.9	95.8	102.0	1,973	110.3
Esophagus	9.3	4.9	4.8	4.3	4.9	103	5.5
Stomach	22.4	16.0	14.0	11.6	19.1	294	16.5
Small Intestine	3.5	2.8	1.7	2.1	1.4	43	2.2
Colon and Rectum	68.6	58.7	54.6	47.3	46.3	953	54.4
Colon excluding Rectum	46.4	42.5	36.6	34.9	31.3	639	37.9
Rectum and Rectosigmoid Junction	22.1	16.1	18.0	12.4	14.9	314	16.5
Anus, Anal Canal and Anorectum	-	-	1.3	-	1.8	25	1.0
Liver and Intrahepatic Bile Duct	14.5	14.5	13.0	12.4	10.2	251	12.7
Liver	14.1	14.0	12.4	11.7	10.0	242	12.3
Intrahepatic Bile Duct	-	-	-	-	-	9	0.4
Gallbladder	-	-	1.8	-	1.6	18	1.0
Other Biliary	1.9	1.0	4.3	2.4	3.5	45	2.7
Pancreas	15.9	9.5	14.2	13.4	12.4	219	13.0
<b>Respiratory System</b>	75.2	62.4	58.7	51.4	51.1	952	59.1
Larynx	8.5	4.4	7.6	5.3	6.6	117	6.5
Lung and Bronchus	65.2	56.6	49.4	45.0	43.1	802	51.2
<b>Bones and Joints</b>	0.7	0.7	1.0	0.6	1.2	31	0.8
<b>Soft Tissue (Including Heart)</b>	2.6	2.1	3.3	3.0	3.0	68	2.8
<b>Skin (Excluding Basal and Squamous)</b>	8.5	3.5	4.1	6.4	5.1	112	5.5
Melanoma of the Skin	7.1	2.6	2.5	5.6	4.6	89	4.5

Rates are per 100,000 population and age-adjusted to the 2000 U.S. population standard.

- Counts and rates are suppressed when fewer than 5 cases to ensure confidentiality and statistical reliability.

**Table 7 (continued). Age-adjusted Incidence Rates, Hispanic Males**

Cancer Site	Rates					Cases 2004-2008	Rates
	2004	2005	2006	2007	2008 Prelim.		
<b>Breast</b>	2.6	1.8	-	-	-	21	1.2
<b>Male Genital System</b>	168.9	172.1	171.0	153.4	150.2	2,855	162.3
Prostate	162.2	168.5	165.3	146.7	142.8	2,658	156.2
Testis	5.1	2.3	3.6	4.4	4.5	156	4.0
Penis	1.5	-	2.1	2.4	3.0	40	2.1
<b>Urinary System</b>	51.8	51.6	44.4	48.9	38.0	759	46.6
Urinary Bladder (Including in situ)	33.5	31.4	32.0	30.4	21.4	422	29.4
Kidney and Renal Pelvis	17.6	18.0	11.4	17.5	15.5	324	16.0
Ureter	-	-	-	-	-	5	0.4
<b>Eye and Orbit</b>	-	-	-	-	-	14	0.5
<b>Brain and Other Nervous System</b>	7.4	8.5	8.1	7.0	7.1	202	7.6
Brain	6.8	8.3	7.6	7.0	6.6	194	7.2
<b>Endocrine System</b>	5.2	5.6	4.5	5.1	5.7	146	5.2
Thyroid	5.1	4.5	4.1	4.4	4.6	127	4.5
<b>Lymphomas</b>	27.0	23.1	24.8	22.0	25.9	554	24.4
Hodgkin Lymphoma	3.1	3.2	3.4	4.5	2.7	101	3.4
Non-Hodgkin Lymphoma	23.9	19.9	21.4	17.6	23.2	453	21.1
<b>Myelomas</b>	11.1	7.5	5.1	5.9	6.8	128	7.2
<b>Leukemias</b>	11.2	13.4	12.0	11.8	11.8	272	12.1
Lymphocytic Leukemia	5.2	4.8	6.3	4.3	3.7	115	4.8
Acute Lymphocytic Leukemia	1.9	2.2	2.3	2.0	1.2	69	1.9
Chronic Lymphocytic Leukemia	2.9	2.0	3.2	2.4	2.1	37	2.5
Myeloid and Monocytic Leukemia	5.3	7.4	4.5	6.4	7.3	138	6.2
Acute Myeloid Leukemia	4.9	4.5	2.3	3.2	3.5	76	3.6
Acute Monocytic Leukemia	-	-	-	-	-	7	0.3
Chronic Myeloid Leukemia	-	2.6	1.3	2.8	2.5	49	2.0
Other Leukemia	-	-	-	1.1	-	19	1.0
<b>Mesothelioma</b>	2.2	-	1.9	-	-	18	1.2
<b>Kaposi Sarcoma</b>	3.0	1.8	1.9	2.0	0.7	43	1.9
<b>Ill-Defined &amp; Unspecified Sites</b>	12.3	13.4	11.9	8.5	6.7	162	10.3

Rates are per 100,000 population and age-adjusted to the 2000 U.S. population standard.

- Counts and rates are suppressed when fewer than 5 cases to ensure confidentiality and statistical reliability.

**Table 8. Age-adjusted Incidence Rates, Hispanic Females**

Cancer Site	Rates					Cases 2004-2008	Rates
	2004	2005	2006	2007	2008		
<b>All Sites</b>	396.2	353.7	345.0	329.3	333.4	8,506	349.9
					Prelim.		
<b>Oral Cavity and Pharynx</b>	4.7	5.3	4.7	4.0	5.2	113	4.8
Lip	-	-	-	-	-	-	-
Tongue	-	1.4	1.0	1.0	1.3	27	1.1
Salivary Gland	-	-	-	-	1.6	22	0.9
Floor of Mouth	1.4	-	-	-	-	9	0.4
Gum and Other Mouth	-	1.7	1.3	1.4	1.3	28	1.2
Nasopharynx	-	-	-	-	-	8	0.3
Tonsil	-	-	0.9	-	-	10	0.4
Oropharynx	-	-	-	-	-	-	-
Hypopharynx	-	-	-	-	-	-	-
<b>Digestive System</b>	91.1	70.4	74.9	63.2	62.3	1,564	71.6
Esophagus	3.9	-	2.2	1.3	2.2	41	2.1
Stomach	14.9	7.5	8.2	8.6	8.6	207	9.4
Small Intestine	2.4	1.8	1.3	-	2.5	36	1.7
Colon and Rectum	42.7	39.1	39.2	32.0	29.8	803	36.2
Colon excluding Rectum	33.4	28.6	29.3	25.2	21.5	589	27.3
Rectum and Rectosigmoid Junction	9.3	10.5	9.9	6.9	8.3	214	8.9
Anus, Anal Canal and Anorectum	2.0	2.5	1.6	1.5	2.2	44	1.9
Liver and Intrahepatic Bile Duct	7.0	4.8	6.4	5.3	3.8	115	5.4
Liver	5.6	3.7	5.4	3.9	3.4	93	4.4
Intrahepatic Bile Duct	1.4	1.1	-	1.4	-	22	1.0
Gallbladder	2.9	2.2	2.2	3.5	1.3	48	2.4
Other Biliary	1.4	2.1	2.0	-	1.4	33	1.5
Pancreas	12.6	7.9	10.7	8.3	8.4	199	9.5
<b>Respiratory System</b>	40.7	29.0	30.7	34.0	27.1	686	32.1
Larynx	1.8	-	1.1	-	-	20	0.9
Lung and Bronchus	38.0	27.4	28.5	33.1	26.1	647	30.4
<b>Bones and Joints</b>	1.7	1.2	1.0	0.8	1.3	39	1.2
<b>Soft Tissue (Including Heart)</b>	3.4	2.3	3.4	1.6	3.2	79	2.8
<b>Skin (Excluding Basal and Squamous)</b>	7.5	3.8	4.9	6.6	5.5	139	5.6
Melanoma of the Skin	6.4	3.4	3.4	5.1	4.1	111	4.4
<b>Breast (Invasive)</b>	99.7	104.6	89.3	92.1	89.8	2,409	94.8
In situ (not included in All Sites)	23.8	22.7	27.1	25.7	27.5	671	25.4

Rates are per 100,000 population and age-adjusted to the 2000 U.S. population standard.

- Counts and rates are suppressed when fewer than 5 cases to ensure confidentiality and statistical reliability.

**Table 8 (continued). Age-adjusted Incidence Rates, Hispanic Females**

Cancer Site	Rates					Cases	Rates
	2004	2005	2006	2007	2008	2004-2008	
					Prelim.		
<b>Female Genital System</b>	52.4	52.5	51.5	47.5	51.4	1,305	51.0
Cervix Uteri	17.4	14.2	14.1	13.2	12.9	404	14.3
Corpus and Uterus, NOS	20.8	23.4	20.7	20.2	23.5	533	21.7
Corpus Uteri	19.7	22.1	20.0	19.6	22.9	514	20.9
Uterus, NOS	1.1	1.3	-	-	-	19	0.8
Ovary	11.2	12.2	10.9	10.3	12.0	286	11.3
Vagina	-	-	1.4	-	-	19	0.9
Vulva	2.0	1.6	2.4	1.7	1.6	41	1.8
<b>Urinary System</b>	17.8	15.2	17.0	13.0	17.1	363	16.0
Urinary Bladder (Including in situ)	8.0	7.5	6.6	4.4	7.5	145	6.8
Kidney and Renal Pelvis	9.9	7.3	10.2	8.0	9.0	211	8.9
Ureter	-	-	-	-	-	-	-
<b>Eye and Orbit</b>	-	-	-	-	-	12	0.4
<b>Brain and Other Nervous System</b>	5.9	3.9	4.4	6.5	3.9	133	4.9
Brain	5.6	3.6	4.4	6.3	3.9	129	4.7
<b>Endocrine System</b>	21.1	17.4	18.3	21.0	25.1	612	20.7
Thyroid	19.9	17.1	18.0	20.5	24.5	597	20.1
<b>Lymphomas</b>	21.7	24.8	19.7	18.7	19.8	513	20.8
Hodgkin Lymphoma	2.3	4.1	2.3	2.8	3.2	93	2.9
Non-Hodgkin Lymphoma	19.4	20.7	17.4	15.9	16.6	420	17.9
<b>Myelomas</b>	6.9	6.5	5.7	3.4	4.7	121	5.3
<b>Leukemias</b>	9.1	7.2	7.4	10.7	8.9	226	8.7
Lymphocytic Leukemia	4.9	3.3	2.5	4.4	3.2	101	3.6
Acute Lymphocytic Leukemia	2.2	1.9	1.3	2.6	2.1	66	2.0
Chronic Lymphocytic Leukemia	2.7	1.4	1.1	1.4	-	30	1.4
Myeloid and Monocytic Leukemia	3.5	2.7	4.9	5.4	4.9	109	4.3
Acute Myeloid Leukemia	2.2	1.9	2.1	3.2	3.8	66	2.7
Acute Monocytic Leukemia	-	-	-	-	-	-	-
Chronic Myeloid Leukemia	1.3	-	2.6	1.8	1.0	36	1.4
Other Leukemia	-	1.2	-	-	-	16	0.7
<b>Mesothelioma</b>	-	-	-	-	-	8	0.4
<b>Kaposi Sarcoma</b>	-	-	-	-	-	8	0.4
<b>Ill-Defined &amp; Unspecified Sites</b>	11.4	8.7	11.0	4.7	7.3	176	8.5

Rates are per 100,000 population and age-adjusted to the 2000 U.S. population standard.

- Counts and rates are suppressed when fewer than 5 cases to ensure confidentiality and statistical reliability.

**Table 9. Age-adjusted Incidence Rates, Asian and Pacific Islander Males and Females 2004-2008 Combined**

Cancer Site	Male Rate	Male Cases	Female Rate	Female Cases
<b>All Sites</b>	288.7	3,161	258.8	3,648
<b>Oral Cavity and Pharynx</b>	11.4	149	3.6	50
Lip	-	-	-	-
Tongue	2.3	32	1.3	16
Salivary Gland	1.0	14	0.4	8
Floor of Mouth	0.8	11	-	-
Gum and Other Mouth	2.9	33	0.5	6
Nasopharynx	2.6	38	0.7	11
Tonsil	0.3	6	-	-
Oropharynx	-	-	-	-
Hypopharynx	0.9	9	-	-
<b>Digestive System</b>	78.9	870	50.8	617
Esophagus	3.3	37	1.2	12
Stomach	16.2	163	8.9	115
Small Intestine	1.4	16	0.8	11
Colon and Rectum	32.4	366	24.4	298
Colon excluding Rectum	18.2	197	17.6	212
Rectum and Rectosigmoid Junction	14.3	169	6.8	86
Anus, Anal Canal and Anorectum	-	-	-	-
Liver and Intrahepatic Bile Duct	13.1	160	4.4	52
Liver	12.7	156	4.4	52
Intrahepatic Bile Duct	-	-	0.0	0
Gallbladder	1.4	15	1.6	19
Other Biliary	1.6	14	2.1	21
Pancreas	8.3	86	5.8	68
<b>Respiratory System</b>	40.6	385	24.6	282
Larynx	1.9	22	-	-
Lung and Bronchus	37.6	348	23.8	270
<b>Bones and Joints</b>	-	-	0.6	10
<b>Soft Tissue (Including Heart)</b>	1.5	21	1.8	26
<b>Skin (Excluding Basal and Squamous)</b>	2.4	26	1.6	23
Melanoma of the Skin	2.0	19	1.3	18
<b>Breast (Invasive)</b>	1.1	11	85.2	1,312
In situ (not included in All Sites)	-	-	31.2	499

Rates are per 100,000 and age-adjusted to the 2000 U.S. population standard.

- Counts and rates are suppressed when fewer than 5 cases to ensure confidentiality and statistical reliability.

**Table 9 (continued). Age-adjusted Incidence Rates, Asian and Pacific Islander Males and Females 2004-2008 Combined**

Cancer Site	Male Rate	Male Cases	Female Rate	Female Cases
<b>Female Genital System</b>	*	*	35.5	529
Cervix Uteri	*	*	6.6	100
Corpus and Uterus, NOS	*	*	17.8	265
Corpus Uteri	*	*	17.5	260
Uterus, NOS	*	*	0.3	5
Ovary	*	*	9.1	137
Vagina	*	*	0.8	10
Vulva	*	*	0.8	11
<b>Male Genital System</b>	77.4	828	*	*
Prostate	74.5	784	*	*
Testis	2.1	36	*	*
Penis	0.3	5	*	*
<b>Urinary System</b>	26.1	271	8.2	104
Urinary Bladder (Including in situ)	16.2	152	3.4	38
Kidney and Renal Pelvis	9.0	111	4.4	62
Ureter	0.7	6	-	-
<b>Eye and Orbit</b>	0.5	8	-	-
<b>Brain and Other Nervous System</b>	4.2	63	4.0	57
Brain	3.8	57	3.5	49
<b>Endocrine System</b>	7.8	115	19.2	329
Thyroid	6.1	94	18.6	321
<b>Lymphomas</b>	17.2	202	10.7	140
Hodgkin Lymphoma	1.9	30	1.1	17
Non-Hodgkin Lymphoma	15.3	172	9.6	123
<b>Myelomas</b>	4.9	51	2.7	34
<b>Leukemias</b>	8.0	98	5.6	81
Lymphocytic Leukemia	4.2	52	2.0	26
Acute Lymphocytic Leukemia	2.2	30	1.2	18
Chronic Lymphocytic Leukemia	1.8	19	0.5	5
Myeloid and Monocytic Leukemia	3.6	43	3.5	51
Acute Myeloid Leukemia	2.4	26	2.5	36
Acute Monocytic Leukemia	-	-	-	-
Chronic Myeloid Leukemia	0.9	13	0.8	12
Other Leukemia	-	-	-	-
<b>Mesothelioma</b>	1.1	9	-	-
<b>Kaposi Sarcoma</b>	-	-	-	-
<b>Ill-Defined &amp; Unspecified Sites</b>	5.5	47	4.5	50

Rates are per 100,000 population and age-adjusted to the 2000 U.S. population standard.

\* Non-applicable gender.

- Counts and rates are suppressed when fewer than 5 cases to ensure confidentiality and statistical reliability.

**Table 10. Benign and Borderline Brain Tumor Incidence Rates, New Jersey, 2004-2008**

	Site Group	Rates					Cases	Rates
		2004	2005	2006	2007	2008 Prelim.	2004-2008	
<b>Total</b>	Brain	0.8	1.0	1.0	0.8	1.1	411	0.9
	Intracranial Meninges	5.5	5.8	5.7	5.3	5.9	2,639	5.6
	Cranial Nerves and other CNS	1.3	1.4	1.3	1.3	1.3	601	1.3
	Tumors of the Sellar Region	2.1	2.5	2.7	2.2	2.9	1,105	2.5
	Spinal Cord	0.5	0.6	0.7	0.4	0.6	247	0.6
	Spinal Meninges	0.5	0.4	0.4	0.3	0.4	184	0.4
	<b>Total</b>		10.7	11.7	11.7	10.4	12.0	5,187
<b>Male</b>	Brain	0.7	1.0	1.1	1.0	1.5	223	1.1
	Intracranial Meninges	3.4	3.9	3.8	3.7	4.2	760	3.8
	Cranial Nerves and other CNS	1.3	1.3	1.4	1.1	1.2	273	1.3
	Tumors of the Sellar Region	2.1	2.5	2.7	2.3	2.6	515	2.4
	Spinal Cord	0.5	0.5	0.7	0.7	0.5	122	0.6
	Spinal Meninges	0.3	0.2	0.2	-	0.2	39	0.2
	<b>Total</b>		8.4	9.3	9.7	8.8	10.2	1,932
<b>Female</b>	Brain	0.8	1.0	0.9	0.7	0.8	188	0.8
	Intracranial Meninges	7.1	7.5	7.3	6.8	7.3	1,879	7.2
	Cranial Nerves and other CNS	1.3	1.5	1.2	1.4	1.3	328	1.4
	Tumors of the Sellar Region	2.2	2.6	2.7	2.2	3.2	590	2.6
	Spinal Cord	0.4	0.7	0.8	0.2	0.6	125	0.5
	Spinal Meninges	0.7	0.5	0.6	0.5	0.6	145	0.6
	<b>Total</b>		12.5	14.0	13.6	11.9	13.8	3,255
<b>White</b>	Brain	0.8	1.1	1.0	0.8	1.1	330	1.0
	Intracranial Meninges	5.4	5.7	5.7	5.1	5.7	2,149	5.5
	Cranial Nerves and other CNS	1.4	1.5	1.4	1.3	1.4	515	1.4
	Tumors of the Sellar Region	1.9	2.1	2.4	2.1	2.4	767	2.2
	Spinal Cord	0.5	0.6	0.8	0.5	0.6	208	0.6
	Spinal Meninges	0.5	0.4	0.4	0.3	0.4	156	0.4
	<b>Total</b>		10.5	11.4	11.6	10.2	11.6	4,125
<b>Black</b>	Brain	0.4	0.6	0.8	-	1.2	39	0.7
	Intracranial Meninges	6.1	5.7	6.0	5.5	6.6	318	6.0
	Cranial Nerves and other CNS	0.5	-	-	0.4	0.6	24	0.4
	Tumors of the Sellar Region	3.5	5.1	4.2	2.9	5.4	240	4.2
	Spinal Cord	-	0.4	0.4	-	-	18	0.3
	Spinal Meninges	-	-	-	-	-	14	0.2
	<b>Total</b>		11.1	12.2	11.9	9.6	14.4	653

Rates are per 100,000 population and age-adjusted to the 2000 U.S. population standard.

- Counts and rates are suppressed when fewer than 5 cases to ensure confidentiality and statistical reliability.

**Table 11. Comparative Incidence Rates, New Jersey and U.S., 2003-2007  
Males**

Cancer Site	New Jersey 2003-2007					United States 2003-2007					
	Population:	All Races	White	Black	API*	Hispanic*	All Races	White	Black	API*	Hispanic*
All Sites		598.2	595.5	631.2	301.7	484.6	552.5	544.9	623.1	332.3	426.1
Prostate		172.4	159.7	248.8	78.1	158.9	153.5	143.8	230.0	81.0	128.0
Lung		78.3	78.7	89.6	38.3	53.1	84.9	84.3	103.5	49.9	48.0
Colorectal		62.6	62.7	67.1	33.8	55.0	57.1	56.1	67.2	42.7	49.2
Melanoma		26.5	30.0	1.3	2.2	4.7	23.1	25.4	1.1	1.6	4.6
Non-Hodgkin Lymphoma		25.6	26.5	17.9	15.2	20.8	23.2	23.7	16.8	14.5	19.5
Thyroid		6.7	7.2	3.5	5.5	4.2	5.1	5.4	2.7	4.6	4.0

\*API=Asians and Pacific Islanders; Hispanic includes all races.

Source: NAACCR Age-adjusted rates per 100,000 (2000 U.S. population standard).

**Table 12. Comparative Incidence Rates, New Jersey and U.S., 2003-2007  
Females**

Cancer Site	New Jersey 2003-2007					United States 2003-2007					
	Population:	All Races	White	Black	API*	Hispanic*	All Races	White	Black	API*	Hispanic*
All Sites		451.2	464.0	403.2	254.4	356.9	414.7	418.8	392.9	278.1	331.2
Breast (invasive)		128.4	132.9	109.9	80.0	94.6	120.7	121.9	114.6	82.3	91.0
Lung		56.3	58.5	51.9	21.8	31.1	55.6	57.0	51.9	27.7	27.1
Colorectal		46.1	45.4	52.0	26.5	38.5	42.4	41.4	50.7	32.5	34.9
Endometrial (Corpus Uteri)		28.1	29.5	21.6	16.8	20.2	23.2	23.7	19.9	15.4	18.6
Thyroid		20.0	21.5	10.5	16.9	17.6	15.2	15.8	9.3	15.5	14.9
Non-Hodgkin Lymphoma		17.7	18.4	13.0	9.2	17.2	16.3	16.8	11.7	10.3	15.1
Melanoma		17.3	20.3	1.2	1.6	4.9	15.0	16.9	1.0	1.3	4.4

\*API=Asians and Pacific Islanders; Hispanic includes all races.

Source: NAACCR Age-adjusted rates per 100,000 (2000 U.S. population standard).

**Table 13. Age-adjusted Mortality Rates, Males All Races Combined**

Cancer Site	Rates				Cases 2004-2007	Rates
	2004	2005	2006	2007		
<b>All Sites</b>	222.4	222.1	215.7	215.7	33,553	218.9
<b>Oral Cavity and Pharynx</b>	3.5	3.5	3.4	3.3	561	3.4
Lip	-	-	0.0	0.0	-	-
Tongue	1.2	1.0	0.9	1.0	170	1.0
Salivary Gland	0.2	0.3	0.4	0.2	44	0.3
Floor of Mouth	-	-	-	-	12	0.1
Gum and Other Mouth	0.4	0.3	0.3	0.4	54	0.3
Nasopharynx	0.3	0.3	0.3	0.4	52	0.3
Tonsil	0.2	0.3	0.2	0.2	38	0.2
Oropharynx	0.3	0.4	0.4	0.2	56	0.3
Hypopharynx	-	0.1	-	0.1	19	0.1
<b>Digestive System</b>	59.0	59.3	58.7	59.2	9,195	59.1
Esophagus	7.0	8.0	7.8	6.9	1,194	7.4
Stomach	6.9	6.3	5.7	6.1	963	6.3
Small Intestine	0.3	0.4	0.5	0.3	62	0.4
Colon and Rectum	23.1	22.6	22.4	22.4	3,444	22.6
Colon excluding Rectum	19.4	18.5	18.8	19.1	2,865	19.0
Rectum and Rectosigmoid Junction	3.7	4.1	3.6	3.3	579	3.7
Anus, Anal Canal and Anorectum	0.1	0.1	0.1	0.2	26	0.2
Liver and Intrahepatic Bile Duct	7.2	8.0	7.7	6.9	1,212	7.5
Liver	6.0	6.5	6.1	5.8	998	6.1
Intrahepatic Bile Duct	1.2	1.5	1.6	1.1	214	1.4
Gallbladder	0.7	0.5	0.5	0.9	96	0.6
Pancreas	12.9	12.3	12.9	14.3	2,044	13.1
<b>Respiratory System</b>	64.6	64.8	61.9	61.5	9,780	63.2
Larynx	2.6	2.4	2.5	2.1	379	2.4
Lung and Bronchus	61.6	61.7	59.1	58.9	9,326	60.3
<b>Bones and Joints</b>	0.4	0.3	0.6	0.5	73	0.5
<b>Soft Tissue (Including Heart)</b>	1.2	1.6	1.8	1.8	252	1.6
<b>Skin (Excluding Basal and Squamous)</b>	5.3	5.4	5.5	5.3	830	5.4
Melanoma of the Skin	3.9	4.1	4.0	4.2	638	4.1

Rates are per 100,000 and age-adjusted to the 2000 U.S. population standard.

- Counts and rates are suppressed when fewer than 5 cases to ensure confidentiality and statistical reliability.

**Table 13 (continued). Age-adjusted Mortality Rates, Males All Races Combined**

Cancer Site	Rates				Cases 2004-2007	Rates
	2004	2005	2006	2007		
<b>Breast</b>	0.7	0.7	0.4	0.3	80	0.5
<b>Male Genital System</b>	24.8	24.2	21.5	23.6	3,343	23.5
Prostate	24.3	23.9	21.2	23.1	3,280	23.1
Testis	0.2	0.1	0.1	0.3	30	0.2
Penis	0.2	0.2	0.1	0.2	29	0.2
<b>Urinary System</b>	13.9	14.3	14.3	14.5	2,134	14.3
Urinary Bladder	8.5	8.8	8.8	9.1	1,284	8.8
Kidney and Renal Pelvis	5.2	5.3	5.1	5.1	807	5.2
Ureter	0.2	-	0.2	-	20	0.1
<b>Eye</b>	-	-	-	-	11	0.1
<b>Brain and Other Nervous System</b>	4.6	4.7	4.3	4.8	764	4.6
<b>Endocrine System</b>	1.0	0.6	0.7	0.8	123	0.8
Thyroid	0.7	0.3	0.5	0.6	81	0.5
<b>Lymphomas</b>	10.2	9.0	9.3	8.6	1,426	9.3
Hodgkin Lymphoma	0.7	0.5	0.5	0.8	101	0.6
Non-Hodgkin Lymphoma	9.5	8.5	8.8	7.8	1,325	8.6
<b>Multiple Myeloma</b>	3.7	4.2	4.5	4.3	639	4.2
<b>Leukemias</b>	9.7	9.3	9.2	9.5	1,425	9.4
Lymphocytic Leukemia	2.6	2.8	2.8	3.0	418	2.8
Acute Lymphocytic Leukemia	0.5	0.5	0.7	0.7	100	0.6
Chronic Lymphocytic Leukemia	2.0	2.2	1.9	2.1	300	2.0
Myeloid and Monocytic Leukemia	4.5	4.0	3.9	4.0	625	4.1
Acute Myeloid Leukemia	3.8	3.6	3.2	3.4	534	3.5
Acute Monocytic Leukemia	-	0.0	-	-	8	0.1
Chronic Myeloid Leukemia	0.4	0.2	0.4	0.3	51	0.3
Other Leukemia	2.7	2.5	2.5	2.5	382	2.5
<b>Ill-Defined &amp; Unspecified Sites</b>	19.6	20.2	19.4	17.6	2,917	19.2

Rates are per 100,000 and age-adjusted to the 2000 U.S. population standard.

- Counts and rates are suppressed when fewer than 5 cases to ensure confidentiality and statistical reliability.

**Table 14. Age-adjusted Mortality Rates, Females All Races Combined**

Cancer Site	Rates				Cases	Rates
	2004	2005	2006	2007	2004-2007	
<b>All Sites</b>	164.4	160.7	162.4	157.6	35,100	161.2
<b>Oral Cavity and Pharynx</b>	1.4	1.3	1.4	1.1	286	1.3
Lip	-	-	-	0.0	-	-
Tongue	0.4	0.4	0.5	0.4	94	0.4
Salivary Gland	0.1	0.1	0.1	0.2	30	0.1
Floor of Mouth	-	-	-	-	5	0.0
Gum and Other Mouth	0.2	0.1	0.2	0.1	34	0.1
Nasopharynx	0.1	-	0.2	0.1	27	0.1
Tonsil	0.1	-	0.1	0.1	19	0.1
Oropharynx	0.1	0.2	0.2	-	28	0.1
Hypopharynx	-	-	-	-	10	0.0
<b>Digestive System</b>	38.1	36.3	37.3	35.1	8,199	36.7
Esophagus	1.9	1.8	1.8	1.7	394	1.8
Stomach	3.3	3.7	3.3	2.7	724	3.3
Small Intestine	0.2	0.3	0.2	0.3	60	0.3
Colon and Rectum	16.4	16.3	16.1	15.6	3,661	16.1
Colon excluding Rectum	14.2	14.1	13.6	13.2	3,147	13.8
Rectum and Rectosigmoid Junction	2.2	2.2	2.4	2.4	514	2.3
Anus, Anal Canal and Anorectum	0.3	0.2	0.1	0.2	39	0.2
Liver and Intrahepatic Bile Duct	3.5	2.8	3.2	3.0	684	3.1
Liver	2.4	1.9	1.9	1.7	433	2.0
Intrahepatic Bile Duct	1.1	0.9	1.3	1.3	251	1.2
Gallbladder	1.1	0.9	1.0	1.0	222	1.0
Pancreas	10.2	9.3	10.3	9.4	2,165	9.8
<b>Respiratory System</b>	40.9	39.9	39.9	39.6	8,588	40.1
Larynx	0.4	0.6	0.5	0.5	111	0.5
Lung and Bronchus	40.3	39.1	39.2	39.0	8,438	39.4
<b>Bones and Joints</b>	0.4	0.2	0.3	0.4	63	0.3
<b>Soft Tissue (Including Heart)</b>	1.1	1.6	1.1	1.2	266	1.3
<b>Skin (Excluding Basal and Squamous)</b>	2.2	2.3	2.0	2.1	472	2.2
Melanoma of the Skin	1.8	1.9	1.7	1.7	373	1.8
<b>Breast</b>	26.1	27.0	27.1	26.1	5,682	26.5

Rates are per 100,000 and age-adjusted to the 2000 U.S. population standard.

- Counts and rates are suppressed when fewer than 5 cases to ensure confidentiality and statistical reliability.

**Table 14 (continued). Age-adjusted Mortality Rates, Females All Races Combined**

Cancer Site	Rates				Cases 2004-2007	Rates
	2004	2005	2006	2007		
<b>Female Genital System</b>	16.9	16.7	18.6	17.4	3,706	17.4
Cervix Uteri	2.6	2.6	2.9	2.1	514	2.6
Corpus and Uterus, NOS	5.0	5.0	5.5	5.1	1,111	5.2
Corpus Uteri	2.3	1.9	2.2	2.2	459	2.1
Uterus, NOS	2.7	3.1	3.3	2.9	652	3.0
Ovary	8.6	8.4	9.3	9.0	1,891	8.8
Vagina	0.2	0.2	0.2	0.1	44	0.2
Vulva	0.4	0.4	0.5	0.6	107	0.5
<b>Urinary System</b>	5.2	5.1	5.2	4.6	1,143	5.0
Urinary Bladder	2.7	2.5	2.8	2.4	600	2.6
Kidney and Renal Pelvis	2.3	2.5	2.3	2.2	507	2.3
Ureter	0.1	0.1	0.1	-	22	0.1
<b>Eye</b>	-	-	-	-	7	0.0
<b>Brain and Other Nervous System</b>	3.3	3.0	2.9	3.1	629	3.1
<b>Endocrine System</b>	1.1	0.8	0.9	0.7	180	0.9
Thyroid	0.7	0.5	0.6	0.4	124	0.6
<b>Lymphomas</b>	6.3	5.9	6.3	6.4	1,370	6.2
Hodgkin Lymphoma	0.4	0.4	0.5	0.5	87	0.4
Non-Hodgkin Lymphoma	5.9	5.5	5.8	5.9	1,283	5.8
<b>Multiple Myeloma</b>	2.9	2.9	2.9	2.8	631	2.9
<b>Leukemias</b>	5.8	5.0	5.0	5.2	1,155	5.2
Lymphocytic Leukemia	1.3	1.5	1.1	1.1	280	1.2
Acute Lymphocytic Leukemia	0.4	0.5	0.4	0.3	73	0.4
Chronic Lymphocytic Leukemia	0.8	1.0	0.6	0.7	193	0.8
Myeloid and Monocytic Leukemia	2.8	2.2	2.2	2.4	508	2.4
Acute Myeloid Leukemia	2.4	1.8	1.9	1.9	426	2.0
Acute Monocytic Leukemia	-	-	-	0.1	6	0.0
Chronic Myeloid Leukemia	0.2	0.3	0.2	0.3	53	0.2
Other Leukemia	1.8	1.3	1.7	1.8	367	1.6
<b>Ill-Defined &amp; Unspecified Sites</b>	12.7	12.7	11.4	11.9	2,723	12.2

Rates are per 100,000 and age-adjusted to the 2000 U.S. population standard.

- Counts and rates are suppressed when fewer than 5 cases to ensure confidentiality and statistical reliability.

**Table 15. Age-adjusted Mortality Rates, White Males**

Cancer Site	Rates				Cases 2004-2007	Rates
	2004	2005	2006	2007		
<b>All Sites</b>	220.6	222.9	218.5	218.2	28,907	220.0
<b>Oral Cavity and Pharynx</b>	3.4	2.9	3.4	2.8	429	3.1
Lip	-	-	0.0	0.0	-	-
Tongue	1.2	0.9	0.9	0.9	136	1.0
Salivary Gland	0.3	0.3	0.4	0.3	39	0.3
Floor of Mouth	-	-	-	-	7	0.0
Gum and Other Mouth	0.4	0.3	0.3	0.3	43	0.3
Nasopharynx	0.3	0.2	0.2	0.3	35	0.3
Tonsil	0.2	0.2	0.3	-	28	0.2
Oropharynx	0.3	0.4	0.4	0.1	41	0.3
Hypopharynx	-	-	-	0.2	14	0.1
<b>Digestive System</b>	57.5	58.9	58.8	58.8	7,773	58.5
Esophagus	7.1	8.1	7.5	7.4	1,027	7.5
Stomach	6.3	6.0	5.5	5.3	761	5.8
Small Intestine	0.3	0.5	0.5	0.3	51	0.4
Colon and Rectum	22.9	22.3	22.8	22.7	2,963	22.7
Colon excluding Rectum	19.3	18.1	19.1	19.3	2,470	19.0
Rectum and Rectosigmoid Junction	3.6	4.1	3.7	3.4	493	3.7
Anus, Anal Canal and Anorectum	-	0.1	-	0.2	18	0.1
Liver and Intrahepatic Bile Duct	6.5	7.5	7.6	6.6	962	7.1
Liver	5.2	5.9	5.9	5.4	769	5.6
Intrahepatic Bile Duct	1.3	1.5	1.7	1.2	193	1.4
Gallbladder	0.7	0.5	0.5	0.8	81	0.6
Pancreas	12.8	12.8	13.3	14.3	1,773	13.3
<b>Respiratory System</b>	64.3	65.3	62.7	63.1	8,453	63.8
Larynx	2.4	2.0	2.1	2.0	289	2.1
Lung and Bronchus	61.2	62.7	60.2	60.6	8,096	61.2
<b>Bones and Joints</b>	0.5	0.3	0.7	0.5	63	0.5
<b>Soft Tissue (Including Heart)</b>	1.1	1.6	2.0	1.9	218	1.6
<b>Skin (Excluding Basal and Squamous)</b>	6.0	6.2	6.3	5.9	806	6.1
Melanoma of the Skin	4.5	4.8	4.6	4.7	624	4.7

Rates are per 100,000 and age-adjusted to the 2000 U.S. population standard.

- Counts and rates are suppressed when fewer than 5 cases to ensure confidentiality and statistical reliability.

**Table 15 (continued). Age-adjusted Mortality Rates, White Males**

Cancer Site	Rates				Cases 2004-2007	Rates
	2004	2005	2006	2007		
<b>Breast</b>	0.7	0.7	0.4	0.3	66	0.5
<b>Male Genital System</b>	22.4	22.5	19.8	21.9	2,699	21.6
Prostate	21.9	22.2	19.5	21.2	2,638	21.2
Testis	0.3	0.2	-	0.3	28	0.2
Penis	0.2	0.2	0.2	0.3	29	0.2
<b>Urinary System</b>	14.8	15.1	15.2	15.2	1,953	15.1
Urinary Bladder	8.9	9.5	9.4	9.8	1,197	9.4
Kidney and Renal Pelvis	5.6	5.4	5.2	5.2	713	5.3
Ureter	0.2	-	0.2	-	20	0.2
<b>Eye</b>	-	-	-	-	11	0.1
<b>Brain and Other Nervous System</b>	5.2	5.1	4.8	5.1	694	5.1
<b>Endocrine System</b>	1.1	0.6	0.7	0.7	103	0.8
Thyroid	0.7	0.3	0.5	0.6	72	0.5
<b>Lymphomas</b>	10.5	9.3	9.8	9.3	1,276	9.7
Hodgkin Lymphoma	0.7	0.5	0.5	0.9	86	0.7
Non-Hodgkin Lymphoma	9.9	8.8	9.2	8.4	1,190	9.1
<b>Multiple Myeloma</b>	3.5	4.1	4.5	4.3	536	4.1
<b>Leukemias</b>	10.1	9.8	9.8	10.3	1,292	10.0
Lymphocytic Leukemia	2.6	3.0	2.9	3.2	373	2.9
Acute Lymphocytic Leukemia	0.5	0.5	0.7	0.9	83	0.6
Chronic Lymphocytic Leukemia	2.1	2.3	2.0	2.2	273	2.1
Myeloid and Monocytic Leukemia	4.6	4.3	4.2	4.4	572	4.4
Acute Myeloid Leukemia	4.0	3.9	3.5	3.7	494	3.8
Acute Monocytic Leukemia	-	0.0	-	-	7	0.1
Chronic Myeloid Leukemia	0.4	0.2	0.4	0.4	42	0.3
Other Leukemia	2.8	2.6	2.7	2.7	347	2.7
<b>Ill-Defined and Unspecified Sites</b>	19.6	20.4	19.7	18.0	2,535	19.4

Rates are per 100,000 and age-adjusted to the 2000 U.S. population standard.

- Counts and rates are suppressed when fewer than 5 cases to ensure confidentiality and statistical reliability.

**Table 16. Age-adjusted Mortality Rates, White Females**

Cancer Site	Rates				Cases 2004-2007	Rates
	2004	2005	2006	2007		
<b>All Sites</b>	166.0	161.9	163.1	160.2	30,182	162.7
<b>Oral Cavity and Pharynx</b>	1.3	1.3	1.4	1.1	233	1.3
Lip	-	-	-	-	-	-
Tongue	0.4	0.4	0.4	0.4	79	0.4
Salivary Gland	0.2	-	-	0.2	24	0.1
Floor of Mouth	-	-	-	-	-	-
Gum and Other Mouth	0.2	0.1	0.1	0.1	29	0.1
Nasopharynx	-	-	0.2	0.1	19	0.1
Tonsil	0.1	-	0.1	0.1	18	0.1
Oropharynx	-	0.2	0.1	-	21	0.1
Hypopharynx	-	-	-	-	7	0.0
<b>Digestive System</b>	37.6	35.6	36.3	34.2	6,939	35.9
Esophagus	1.9	1.7	1.7	1.6	332	1.7
Stomach	3.0	3.3	2.8	2.3	549	2.9
Small Intestine	0.3	0.3	0.2	0.2	49	0.2
Colon and Rectum	16.5	16.1	15.6	15.6	3,137	15.9
Colon excluding Rectum	14.2	13.9	13.0	13.1	2,688	13.6
Rectum and Rectosigmoid Junction	2.3	2.1	2.6	2.4	449	2.4
Anus, Anal Canal and Anorectum	0.2	0.2	0.1	0.2	34	0.2
Liver and Intrahepatic Bile Duct	3.3	2.6	3.1	2.9	565	3.0
Liver	2.2	1.8	1.7	1.6	350	1.8
Intrahepatic Bile Duct	1.1	0.8	1.4	1.3	215	1.2
Gallbladder	1.0	0.9	1.0	0.9	182	1.0
Pancreas	10.1	9.5	10.5	9.2	1,863	9.8
<b>Respiratory System</b>	41.9	41.1	40.9	42.0	7,548	41.5
Larynx	0.4	0.6	0.6	0.4	91	0.5
Lung and Bronchus	41.3	40.4	40.2	41.4	7,424	40.8
<b>Bones and Joints</b>	0.3	0.2	0.3	0.4	51	0.3
<b>Soft Tissue (Including Heart)</b>	1.3	1.5	1.2	1.2	231	1.3
<b>Skin (Excluding Basal and Squamous)</b>	2.6	2.6	2.4	2.3	457	2.5
Melanoma of the Skin	2.1	2.2	2.0	1.9	362	2.0
<b>Breast</b>	25.7	26.9	26.9	26.1	4,761	26.4

Rates are per 100,000 and age-adjusted to the 2000 U.S. population standard.

- Counts and rates are suppressed when fewer than 5 cases to ensure confidentiality and statistical reliability.

**Table 16 (continued). Age-adjusted Mortality Rates, White Females**

Cancer Site	Rates				Cases 2004-2007	Rates
	2004	2005	2006	2007		
<b>Female Genital System</b>	17.1	16.9	18.0	17.5	3,119	17.4
Cervix Uteri	2.4	2.5	2.4	1.8	376	2.3
Corpus and Uterus, NOS	4.9	4.7	5.3	4.8	904	4.9
Corpus Uteri	2.3	2.1	2.3	2.1	397	2.2
Uterus, NOS	2.6	2.6	3.0	2.7	507	2.7
Ovary	9.2	8.9	9.4	9.7	1,675	9.3
Vagina	0.2	0.2	0.2	0.2	37	0.2
Vulva	0.4	0.4	0.5	0.7	99	0.5
<b>Urinary System</b>	5.3	5.2	5.1	4.9	1,006	5.1
Urinary Bladder	2.7	2.5	2.6	2.4	524	2.6
Kidney and Renal Pelvis	2.4	2.6	2.3	2.4	451	2.4
Ureter	0.1	-	0.1	-	18	0.1
<b>Eye</b>	-	-	-	-	6	0.0
<b>Brain and Other Nervous System</b>	3.6	3.4	3.4	3.4	582	3.5
<b>Endocrine System</b>	1.1	0.7	0.9	0.8	157	0.9
Thyroid	0.7	0.5	0.6	0.5	109	0.6
<b>Lymphomas</b>	6.7	6.1	6.7	6.7	1,241	6.6
Hodgkin Lymphoma	0.5	0.3	0.5	0.4	73	0.4
Non-Hodgkin Lymphoma	6.2	5.7	6.2	6.3	1,168	6.1
<b>Multiple Myeloma</b>	2.5	2.5	2.6	2.2	468	2.5
<b>Leukemias</b>	5.9	5.2	5.2	5.4	1,021	5.4
Lymphocytic Leukemia	1.4	1.6	1.1	1.1	259	1.3
Acute Lymphocytic Leukemia	0.5	0.5	0.4	0.3	61	0.4
Chronic Lymphocytic Leukemia	0.9	1.1	0.7	0.8	184	0.9
Myeloid and Monocytic Leukemia	2.9	2.2	2.3	2.3	441	2.4
Acute Myeloid Leukemia	2.5	1.8	2.1	1.9	371	2.1
Acute Monocytic Leukemia	-	-	0.0	0.1	6	0.0
Chronic Myeloid Leukemia	0.2	0.2	0.2	0.3	44	0.2
Other Leukemia	1.6	1.4	1.7	1.9	321	1.6
<b>Ill-Defined &amp; Unspecified Sites</b>	12.9	12.6	11.6	11.9	2,362	12.2

Rates are per 100,000 and age-adjusted to the 2000 U.S. population standard.

- Counts and rates are suppressed when fewer than 5 cases to ensure confidentiality and statistical reliability.

**Table 17. Age-adjusted Mortality Rates, Black Males**

Cancer Site	Rates				Cases 2004-2007	Rates
	2004	2005	2006	2007		
<b>All Sites</b>	283.4	264.2	253.7	255.5	3,912	263.9
<b>Oral Cavity and Pharynx</b>	5.4	8.1	4.4	8.3	113	6.5
Lip	-	-	-	-	-	-
Tongue	1.5	1.9	1.4	2.4	32	1.8
Salivary Gland	-	-	-	-	5	0.3
Floor of Mouth	-	-	-	-	-	-
Gum and Other Mouth	-	-	-	-	7	0.5
Nasopharynx	-	-	-	-	9	0.5
Tonsil	-	1.1	-	-	10	0.5
Oropharynx	-	-	-	-	14	0.7
Hypopharynx	-	-	-	-	5	0.3
<b>Digestive System</b>	77.1	71.6	74.6	74.0	1,145	74.3
Esophagus	8.1	9.7	12.4	6.4	148	9.1
Stomach	11.1	8.0	9.0	13.0	144	10.3
Small Intestine	-	-	-	-	11	0.8
Colon and Rectum	28.7	32.0	27.1	26.0	414	28.4
Colon excluding Rectum	23.7	27.4	22.4	21.7	341	23.8
Rectum and Rectosigmoid Junction	5.1	4.5	4.7	4.3	73	4.6
Anus, Anal Canal and Anorectum	-	-	-	-	8	0.4
Liver and Intrahepatic Bile Duct	11.7	8.5	9.2	9.0	176	9.6
Liver	11.1	7.4	8.5	7.7	159	8.7
Intrahepatic Bile Duct	-	1.1	-	1.2	17	0.9
Gallbladder	-	-	-	-	9	0.6
Pancreas	15.9	11.2	13.9	16.4	222	14.3
<b>Respiratory System</b>	83.5	78.7	72.0	69.2	1,154	75.6
Larynx	5.0	6.2	6.1	4.5	84	5.4
Lung and Bronchus	78.5	71.8	65.8	64.0	1,064	69.8
<b>Bones and Joints</b>	-	-	-	-	10	0.5
<b>Soft Tissue (Including Heart)</b>	1.6	1.7	-	1.7	26	1.4
<b>Skin (Excluding Basal and Squamous)</b>	1.1	-	-	2.2	20	1.4
Melanoma of the Skin	-	-	-	1.7	11	0.9

Rates are per 100,000 and age-adjusted to the 2000 U.S. population standard.

- Counts and rates are suppressed when fewer than 5 cases to ensure confidentiality and statistical reliability.

**Table 17 (continued). Age-adjusted Mortality Rates, Black Males**

Cancer Site	Rates				Cases 2004-2007	Rates
	2004	2005	2006	2007		
<b>Breast</b>	-	1.9	-	-	13	0.9
<b>Male Genital System</b>	54.8	48.2	46.6	49.9	599	49.8
Prostate	54.8	48.2	46.3	49.9	597	49.8
Testis	-	-	-	-	-	-
Penis	-	-	-	-	-	-
<b>Urinary System</b>	9.0	10.0	10.8	12.2	150	10.5
Urinary Bladder	6.1	4.3	6.2	6.0	73	5.6
Kidney and Renal Pelvis	2.9	5.7	4.6	6.2	77	4.9
Ureter	-	-	-	-	-	-
<b>Eye</b>	-	-	-	-	-	-
<b>Brain and Other Nervous System</b>	2.1	3.4	2.4	2.7	47	2.6
<b>Endocrine System</b>	-	-	-	-	11	0.6
Thyroid	-	-	-	-	6	0.4
<b>Lymphomas</b>	8.3	5.8	6.2	4.2	107	6.1
Hodgkin Lymphoma	0.9	-	-	-	11	0.5
Non-Hodgkin Lymphoma	7.4	5.5	5.6	4.0	96	5.6
<b>Multiple Myeloma</b>	7.5	5.8	6.7	6.0	96	6.5
<b>Leukemias</b>	7.7	7.1	5.9	5.8	104	6.6
Lymphocytic Leukemia	2.1	2.3	2.2	2.1	35	2.2
Acute Lymphocytic Leukemia	-	-	0.9	-	10	0.4
Chronic Lymphocytic Leukemia	1.9	-	1.3	2.1	24	1.6
Myeloid and Monocytic Leukemia	3.1	2.5	2.2	1.7	40	2.4
Acute Myeloid Leukemia	1.9	2.1	1.4	1.5	30	1.7
Acute Monocytic Leukemia	-	-	-	-	-	-
Chronic Myeloid Leukemia	-	-	-	-	7	0.4
Other Leukemia	2.5	2.3	1.5	1.9	29	2.0
<b>Ill-Defined &amp; Unspecified Sites</b>	22.8	20.2	20.4	17.9	317	20.3

Rates are per 100,000 and age-adjusted to the 2000 U.S. population standard.

- Counts and rates are suppressed when fewer than 5 cases to ensure confidentiality and statistical reliability.

**Table 18. Age-adjusted Mortality Rates, Black Females**

Cancer Site	Rates				Cases 2004-2007	Rates
	2004	2005	2006	2007		
<b>All Sites</b>	181.0	181.8	187.7	170.9	4,206	180.3
<b>Oral Cavity and Pharynx</b>	2.4	1.5	2.0	1.2	44	1.8
Lip	-	-	-	-	-	-
Tongue	-	-	-	-	11	0.4
Salivary Gland	-	-	-	-	5	0.2
Floor of Mouth	-	-	-	-	-	-
Gum and Other Mouth	-	-	-	-	5	0.2
Nasopharynx	-	-	-	-	5	0.2
Tonsil	-	-	-	-	-	-
Oropharynx	-	-	-	-	6	0.2
Hypopharynx	-	-	-	-	-	-
<b>Digestive System</b>	44.3	47.9	49.2	47.7	1,074	47.3
Esophagus	1.7	2.2	2.7	2.6	55	2.3
Stomach	5.2	7.2	5.5	5.5	131	5.8
Small Intestine	-	-	-	-	11	0.5
Colon and Rectum	18.8	22.7	23.0	19.8	476	21.1
Colon excluding Rectum	16.6	19.4	20.9	17.0	418	18.5
Rectum and Rectosigmoid Junction	2.2	3.3	2.1	2.8	58	2.6
Anus, Anal Canal and Anorectum	-	-	-	-	5	0.2
Liver and Intrahepatic Bile Duct	3.1	4.4	4.9	3.3	93	3.9
Liver	2.7	2.6	3.2	1.9	62	2.6
Intrahepatic Bile Duct	-	1.8	1.7	1.5	31	1.3
Gallbladder	1.7	0.9	1.3	2.2	35	1.5
Pancreas	12.9	9.2	10.1	12.8	253	11.2
<b>Respiratory System</b>	44.5	41.5	41.9	32.7	925	40.1
Larynx	0.9	1.2	-	0.9	19	0.8
Lung and Bronchus	43.4	40.2	41.2	31.8	902	39.1
<b>Bones and Joints</b>	0.7	-	-	-	11	0.4
<b>Soft Tissue (Including Heart)</b>	-	2.3	1.0	1.3	31	1.3
<b>Skin (Excluding Basal and Squamous)</b>	-	-	-	-	9	0.4
Melanoma of the Skin	-	-	-	-	6	0.2
<b>Breast</b>	33.4	30.1	33.5	30.7	775	31.9

Rates are per 100,000 and age-adjusted to the 2000 U.S. population standard.

- Counts and rates are suppressed when fewer than 5 cases to ensure confidentiality and statistical reliability.

**Table 18 (continued). Age-adjusted Mortality Rates, Black Females**

Cancer Site	Rates				Cases 2004-2007	Rates
	2004	2005	2006	2007		
<b>Female Genital System</b>	20.0	18.0	25.0	21.2	509	21.1
Cervix Uteri	5.2	3.8	6.5	4.3	124	4.9
Corpus and Uterus, NOS	6.5	8.0	7.8	9.4	186	7.9
Corpus Uteri	2.9	1.0	2.0	3.4	55	2.3
Uterus, NOS	3.6	7.0	5.8	6.0	131	5.6
Ovary	7.2	5.8	9.5	6.3	174	7.2
Vagina	-	-	-	-	6	0.2
Vulva	-	-	-	-	8	0.3
<b>Urinary System</b>	5.3	4.9	7.6	3.2	116	5.2
Urinary Bladder	3.0	2.4	4.6	2.4	66	3.1
Kidney and Renal Pelvis	2.1	2.4	2.6	0.8	46	2.0
Ureter	-	-	-	-	-	-
<b>Eye</b>	-	-	-	-	-	-
<b>Brain and Other Nervous System</b>	1.8	0.9	0.7	1.8	33	1.3
<b>Endocrine System</b>	-	1.4	-	-	16	0.7
Thyroid	-	0.9	-	-	9	0.4
<b>Lymphomas</b>	3.6	5.2	4.2	4.5	102	4.4
Hodgkin Lymphoma	-	-	-	0.8	13	0.5
Non-Hodgkin Lymphoma	3.3	4.4	3.9	3.7	89	3.8
<b>Multiple Myeloma</b>	6.0	6.8	5.9	7.6	149	6.6
<b>Leukemias</b>	4.9	4.5	4.3	4.3	106	4.5
Lymphocytic Leukemia	-	1.1	0.9	0.8	19	0.8
Acute Lymphocytic Leukemia	-	-	-	-	10	0.4
Chronic Lymphocytic Leukemia	-	-	-	-	9	0.4
Myeloid and Monocytic Leukemia	1.7	2.4	1.9	2.3	49	2.1
Acute Myeloid Leukemia	1.4	1.4	1.7	2.0	38	1.6
Acute Monocytic Leukemia	-	-	-	-	-	-
Chronic Myeloid Leukemia	-	-	-	-	8	0.3
Other Leukemia	2.9	1.0	1.5	1.2	38	1.7
<b>Ill-Defined &amp; Unspecified Sites</b>	12.6	16.1	11.5	13.3	305	13.4

Rates are per 100,000 and age-adjusted to the 2000 U.S. population standard.

- Counts and rates are suppressed when fewer than 5 cases to ensure confidentiality and statistical reliability.

**Table 19. Age-adjusted Mortality Rates, Hispanic Males and Females  
2004-2007 Combined**

Cancer Site	Male Rate	Male Cases	Female Rate	Female Cases
<b>All Sites</b>	127.1	1,597	91.3	1,544
<b>Oral Cavity and Pharynx</b>	1.9	29	1.0	17
Lip	-	-	-	-
Tongue	0.6	9	0.3	5
Salivary Gland	-	-	-	-
Floor of Mouth	-	-	-	-
Gum and Other Mouth	-	-	-	-
Nasopharynx	-	-	0.3	6
Tonsil	-	-	-	-
Oropharynx	-	-	-	-
Hypopharynx	-	-	-	-
<b>Digestive System</b>	42.4	558	29.0	461
Esophagus	3.6	51	0.9	14
Stomach	7.1	95	4.1	68
Small Intestine	-	-	-	-
Colon and Rectum	14.8	187	10.2	166
Colon excluding Rectum	12.2	149	8.6	139
Rectum and Rectosigmoid Junction	2.6	38	1.7	27
Anus, Anal Canal and Anorectum	-	-	-	-
Liver and Intrahepatic Bile Duct	7.0	98	4.2	64
Liver	5.8	80	3.0	45
Intrahepatic Bile Duct	1.2	18	1.2	19
Gallbladder	-	-	1.3	21
Pancreas	8.8	111	7.0	109
<b>Respiratory System</b>	29.2	360	12.7	209
Larynx	2.0	25	0.3	5
Lung and Bronchus	26.9	330	12.3	202
<b>Bones and Joints</b>	0.3	6	0.3	6
<b>Soft Tissue (Including Heart)</b>	0.9	16	0.8	18
<b>Skin (Excluding Basal and Squamous)</b>	0.9	13	0.7	11
Melanoma of the Skin	0.6	10	0.4	7
<b>Breast</b>	-	-	13.7	259

Rates are per 100,000 and age-adjusted to the 2000 U.S. population standard.

- Counts and rates are suppressed when fewer than 5 cases to ensure confidentiality and statistical reliability.

**Table 19 (continued). Age-adjusted Mortality Rates, Hispanic Males and Females  
2004-2007 Combined**

Cancer Site	Male Rate	Male Cases	Female Rate	Female Cases
<b>Female Genital System</b>	*	*	11.0	199
Cervix Uteri	*	*	2.4	53
Corpus and Uterus, NOS	*	*	3.3	54
Corpus Uteri	*	*	1.0	16
Uterus, NOS	*	*	2.3	38
Ovary	*	*	4.6	81
Vagina	*	*	-	-
Vulva	*	*	0.4	6
<b>Male Genital System</b>	16.2	159	*	*
Prostate	15.8	151	*	*
Testis	-	-	*	*
Penis	0.3	5	*	*
<b>Urinary System</b>	7.0	79	2.5	40
Urinary Bladder	3.8	42	1.4	21
Kidney and Renal Pelvis	3.1	36	1.0	17
Ureter	-	-	-	-
<b>Eye</b>	-	-	-	-
<b>Brain and Other Nervous System</b>	2.2	39	2.1	42
<b>Endocrine System</b>	0.3	5	0.5	9
Thyroid	-	-	0.3	5
<b>Lymphomas</b>	6.0	86	5.0	79
Hodgkin Lymphoma	0.6	9	0.4	8
Non-Hodgkin Lymphoma	5.5	77	4.6	71
<b>Multiple Myeloma</b>	2.9	40	2.9	43
<b>Leukemias</b>	4.7	72	3.0	53
Lymphocytic Leukemia	1.3	23	0.8	16
Acute Lymphocytic Leukemia	0.5	13	0.6	13
Chronic Lymphocytic Leukemia	0.7	9	-	-
Myeloid and Monocytic Leukemia	2.2	33	1.1	19
Acute Myeloid Leukemia	2.0	29	0.6	12
Acute Monocytic Leukemia	-	-	-	-
Chronic Myeloid Leukemia	-	-	0.4	6
Other Leukemia	1.2	16	1.1	18
<b>Ill-Defined &amp; Unspecified Sites</b>	11.7	131	6.1	96

Rates are per 100,000 and age-adjusted to the 2000 U.S. population standard.

\* Non-applicable gender

- Counts and rates are suppressed when fewer than 5 cases to ensure confidentiality and statistical reliability.

**Table 20. Age-adjusted Mortality Rates, Asian and Pacific Islander Males and Females 2004-2007 Combined**

Cancer Site	Male Rate	Male Cases	Female Rate	Female Cases
<b>All Sites</b>	99.6	706	71.5	671
<b>Oral Cavity and Pharynx</b>	1.9	19	1.1	9
Lip	-	-	-	-
Tongue	-	-	-	-
Salivary Gland	-	-	-	-
Floor of Mouth	-	-	-	-
Gum and Other Mouth	-	-	-	-
Nasopharynx	0.9	8	-	-
Tonsil	-	-	-	-
Oropharynx	-	-	-	-
Hypopharynx	-	-	-	-
<b>Digestive System</b>	36.2	268	20.4	180
Esophagus	2.3	18	0.9	7
Stomach	8.4	56	4.7	44
Small Intestine	-	-	-	-
Colon and Rectum	8.7	65	5.5	47
Colon excluding Rectum	7.3	52	4.6	40
Rectum and Rectosigmoid Junction	1.4	13	0.9	7
Anus, Anal Canal and Anorectum	-	-	-	-
Liver and Intrahepatic Bile Duct	8.3	71	3.0	26
Liver	7.8	67	2.6	21
Intrahepatic Bile Duct	-	-	0.4	5
Gallbladder	0.9	6	0.6	5
Pancreas	7.0	48	5.0	44
<b>Respiratory System</b>	23.9	163	11.6	99
Larynx	1.0	5	-	-
Lung and Bronchus	22.8	157	11.3	96
<b>Bones and Joints</b>	-	-	-	-
<b>Soft Tissue (Including Heart)</b>	0.8	7	-	-
<b>Skin (Excluding Basal and Squamous)</b>	-	-	0.7	6
Melanoma of the Skin	-	-	0.5	5
<b>Breast</b>	-	-	12.1	138

Rates are per 100,000 and age-adjusted to the 2000 U.S. population standard.

- Counts and rates are suppressed when fewer than 5 cases to ensure confidentiality and statistical reliability.

**Table 20 (continued). Age-adjusted Mortality Rates, Asian and Pacific Islander Males and Females 2004-2007 Combined**

Cancer Site	Male Rate	Male Cases	Female Rate	Female Cases
<b>Female Genital System</b>	*	*	7.2	73
Cervix Uteri	*	*	1.2	14
Corpus and Uterus, NOS	*	*	2.2	20
Corpus Uteri	*	*	0.6	6
Uterus, NOS	*	*	1.6	14
Ovary	*	*	3.6	38
Vagina	*	*	-	-
Vulva	*	*	-	-
<b>Male Genital System</b>	9.5	44	*	*
Prostate	9.5	44	*	*
Testis	-	-	*	*
Penis	-	-	*	*
<b>Urinary System</b>	3.8	29	2.6	20
Urinary Bladder	2.0	12	1.4	10
Kidney and Renal Pelvis	1.8	17	1.0	9
Ureter	-	-	-	-
<b>Eye</b>	-	-	-	-
<b>Brain and Other Nervous System</b>	2.2	23	1.4	14
<b>Endocrine System</b>	1.2	9	0.7	7
Thyroid	-	-	0.7	6
<b>Lymphomas</b>	5.4	43	3.2	26
Hodgkin Lymphoma	-	-	-	-
Non-Hodgkin Lymphoma	5.1	39	3.1	25
<b>Multiple Myeloma</b>	0.9	7	1.3	12
<b>Leukemias</b>	3.9	27	2.8	28
Lymphocytic Leukemia	1.2	9	-	-
Acute Lymphocytic Leukemia	0.7	7	-	-
Chronic Lymphocytic Leukemia	-	-	-	-
Myeloid and Monocytic Leukemia	1.9	12	1.6	18
Acute Myeloid Leukemia	1.5	9	1.6	17
Acute Monocytic Leukemia	-	-	-	-
Chronic Myeloid Leukemia	-	-	-	-
Other Leukemia	0.8	6	1.0	8
<b>Ill-Defined &amp; Unspecified Sites</b>	9.3	62	5.9	54

Rates are per 100,000 and age-adjusted to the 2000 U.S. population standard.

\* Non-applicable gender

- Counts and rates are suppressed when fewer than 5 cases to ensure confidentiality and statistical reliability.

**Table 21. Comparative Mortality Rates, New Jersey and U.S., 2003-2007  
Males**

Cancer Site	New Jersey 2003-2007					United States 2003-2007				
	All Races	White	Black	API*	Hispanic*	All Races	White	Black	API*	Hispanic*
<b>All Sites</b>	222.5	223.1	273.4	99.2	131.1	225.5	222.5	296.6	134.2	150.4
<b>Lung</b>	61.5	62.1	73.2	23.2	28.0	68.8	68.3	87.6	36.7	32.5
<b>Prostate</b>	23.9	21.9	51.8	8.1	16.6	24.7	22.8	54.2	10.6	18.8
<b>Colorectal</b>	23.3	23.4	29.2	8.6	15.8	21.2	20.6	30.5	13.2	15.6

\*API=Asians and Pacific Islanders; Hispanic includes all races.

Source-NAACCR Age-adjusted rates per 100,000 (2000 U.S. population standard)

**Table 22. Comparative Mortality Rates, New Jersey and U.S., 2003-2007  
Females**

Cancer Site	New Jersey 2003-2007					United States 2003-2007				
	All Races	White	Black	API*	Hispanic*	All Races	White	Black	API*	Hispanic*
<b>All Sites</b>	163.2	164.6	182.9	72.3	91.4	155.4	155.0	180.6	94.1	102.2
<b>Lung</b>	39.7	41.0	39.5	12.6	12.5	40.6	41.6	39.6	18.5	14.4
<b>Breast</b>	27.0	26.8	32.4	11.6	13.7	24.0	23.4	32.4	12.2	15.3
<b>Colorectal</b>	16.7	16.5	22.0	6.3	10.1	14.9	14.4	21.0	9.9	10.5

\*API=Asians and Pacific Islanders; Hispanic includes all races.

Source-NAACCR Age-adjusted rates per 100,000 (2000 U.S. population standard)

**Cancer Incidence and Mortality in New Jersey, 2004-2008**

**Table 23. Population Denominators**

	2003						2004					
	All Races		White	White	Black	Black	All Races		White	White	Black	Black
	Male	Female	Male	Female	Male	Female	Male	Female	Male	Female	Male	Female
<1	59,588	56,422	43,261	40,817	10,815	10,338	59,273	56,843	43,060	41,547	10,559	10,027
01-04	232,353	222,024	170,846	162,148	41,235	39,829	234,644	224,155	171,334	162,871	41,798	40,141
05-09	298,301	284,235	221,882	210,951	52,961	50,634	294,602	280,374	219,201	207,689	51,589	49,398
10-14	315,559	300,592	235,864	223,885	57,323	55,892	313,400	298,455	233,350	222,004	57,092	55,143
15-19	282,098	266,760	212,327	199,650	50,317	48,781	287,569	272,402	216,308	203,597	51,377	50,049
20-24	258,543	245,721	190,336	178,340	48,138	47,524	260,753	247,384	191,838	180,282	48,448	46,918
25-29	268,030	259,468	197,551	185,521	43,177	45,845	270,768	260,561	199,217	185,661	44,360	46,681
30-34	306,526	306,976	227,382	223,036	46,868	52,106	298,776	297,348	219,473	214,085	46,025	50,824
35-39	338,985	346,664	261,207	261,874	48,641	55,145	329,976	336,037	252,773	252,031	47,284	53,516
40-44	359,722	367,513	285,091	286,133	47,437	53,817	360,066	367,470	283,562	284,138	48,131	54,829
45-49	328,378	340,052	265,329	269,085	39,691	46,672	335,956	347,642	270,543	274,210	40,842	47,943
50-54	274,472	294,149	224,164	234,734	31,523	40,018	281,185	298,127	229,153	237,703	32,501	40,353
55-59	230,766	251,285	191,593	204,345	24,848	31,882	238,259	260,058	197,434	210,717	25,581	33,205
60-64	173,843	195,309	143,897	158,664	19,394	25,913	178,532	201,503	147,999	163,708	19,492	26,295
65-69	133,583	158,913	111,257	130,428	14,974	20,639	136,384	160,581	113,004	131,243	15,335	20,960
70-74	117,064	151,340	101,392	129,281	11,291	16,442	114,430	147,884	98,210	125,028	11,388	16,848
75-79	96,398	141,256	85,925	124,700	7,763	12,596	95,951	138,465	85,124	121,559	7,871	12,668
80-84	64,159	110,800	58,345	99,999	4,231	8,373	65,481	112,744	59,371	101,387	4,367	8,745
85+	42,339	103,295	38,990	94,718	2,384	6,840	43,087	104,405	39,521	95,583	2,488	6,895
Total	4,180,707	4,402,774	3,266,639	3,418,309	603,011	669,286	4,199,092	4,412,438	3,270,475	3,415,043	606,528	671,438

  

	2005						2006					
	All Races		White	White	Black	Black	All Races		White	White	Black	Black
	Male	Female	Male	Female	Male	Female	Male	Female	Male	Female	Male	Female
<1	56,966	54,356	41,275	39,411	10,104	9,684	55,745	52,895	39,872	37,827	10,321	9,844
01-04	235,463	224,622	170,895	162,725	42,124	40,092	233,240	222,969	169,373	161,829	41,201	39,001
05-09	290,879	277,391	216,363	205,162	50,042	48,353	288,033	274,190	212,730	201,366	49,788	48,333
10-14	308,317	292,949	229,078	217,654	55,979	53,520	303,004	288,201	224,785	213,928	54,455	51,854
15-19	293,951	278,386	220,482	207,601	52,971	51,499	297,402	281,985	222,864	209,841	53,640	52,335
20-24	261,942	248,178	193,197	181,584	48,136	46,253	263,940	250,417	195,134	183,811	48,150	46,120
25-29	274,977	263,655	201,536	187,514	46,054	47,350	276,761	264,574	202,505	188,082	47,522	47,995
30-34	289,422	284,676	210,666	203,168	44,894	48,506	281,349	274,294	203,824	194,169	43,563	46,756
35-39	323,723	328,766	246,286	244,668	46,486	52,773	319,053	322,902	240,646	238,637	46,128	51,882
40-44	356,946	363,556	279,752	279,692	48,148	54,675	350,484	357,290	272,882	272,680	47,766	54,648
45-49	342,512	353,089	273,980	277,200	42,749	49,417	347,495	356,948	277,184	279,659	43,822	50,147
50-54	288,180	303,341	235,122	241,944	32,824	40,605	295,969	309,597	240,706	246,163	33,886	41,463
55-59	247,611	270,273	204,343	217,969	26,900	34,890	256,157	278,563	211,069	223,945	27,860	36,434
60-64	182,633	205,229	151,535	166,747	19,590	26,263	186,919	210,365	155,035	171,030	19,673	26,274
65-69	138,077	162,293	113,866	131,861	15,467	21,450	139,387	164,791	114,685	133,424	15,548	21,708
70-74	112,380	144,791	95,707	121,292	11,481	17,054	112,104	142,583	94,452	118,196	11,776	17,577
75-79	95,555	136,117	84,193	118,737	8,128	12,873	94,742	134,155	83,199	116,370	8,081	13,002
80-84	65,759	112,566	59,276	100,767	4,573	8,939	65,844	111,331	59,018	99,019	4,735	9,222
85+	44,785	107,527	40,987	98,160	2,583	7,182	46,855	111,188	42,775	101,492	2,703	7,268
Total	4,210,078	4,411,759	3,268,539	3,403,856	609,233	671,378	4,214,483	4,409,238	3,262,738	3,391,468	610,618	671,863

  

	2007						2008					
	All Races		White	White	Black	Black	All Races		White	White	Black	Black
	Male	Female	Male	Female	Male	Female	Male	Female	Male	Female	Male	Female
<1	56,848	54,083	40,304	38,332	10,826	10,316	56,578	54,622	39,667	38,364	10,987	10,673
01-04	230,400	219,545	166,541	158,765	40,798	38,670	228,414	217,789	164,229	156,665	40,928	38,818
05-09	286,817	273,373	210,784	199,959	49,838	47,961	288,622	274,307	210,956	199,682	50,188	48,081
10-14	297,618	283,157	220,747	209,957	52,698	50,194	292,864	278,866	217,129	206,658	51,248	48,845
15-19	299,804	283,702	224,095	210,748	54,170	52,635	299,846	283,665	223,544	210,261	54,239	52,606
20-24	265,050	253,065	196,180	186,173	48,217	46,417	267,543	255,330	198,084	187,989	48,671	46,795
25-29	280,091	265,802	204,284	188,825	48,260	48,100	284,384	268,751	206,450	191,027	49,385	48,478
30-34	278,852	269,487	201,592	189,672	43,192	46,075	280,713	268,341	202,636	188,570	43,801	45,664
35-39	313,504	315,004	233,982	230,387	45,771	51,083	307,757	306,595	227,631	222,090	45,038	50,003
40-44	341,274	349,260	264,176	265,028	46,809	53,696	332,263	339,812	255,897	256,295	45,762	52,406
45-49	349,453	357,400	278,026	278,803	44,394	50,893	350,233	357,526	277,210	277,729	45,141	51,335
50-54	305,771	318,420	247,599	252,692	35,515	42,563	315,149	326,671	254,252	258,127	37,138	44,265
55-59	252,993	273,531	207,030	218,393	28,114	36,534	256,341	276,378	209,400	220,291	28,371	36,799
60-64	201,707	226,257	168,229	184,492	20,547	27,655	206,779	231,502	171,709	187,799	21,218	28,492
65-69	144,067	170,362	118,511	137,745	15,742	22,216	152,882	179,708	126,728	146,137	15,955	22,664
70-74	112,083	141,738	93,881	116,892	11,778	17,629	114,022	143,185	94,920	117,574	12,072	17,939
75-79	93,555	132,000	81,356	113,478	8,389	13,407	92,395	129,122	79,882	110,226	8,375	13,564
80-84	66,315	110,900	59,266	98,211	4,811	9,407	66,825	110,436	59,362	97,416	5,043	9,543
85+	48,561	114,194	44,191	103,904	2,820	7,548	50,163	117,019	45,572	106,226	2,892	7,758
Total	4,224,763	4,411,280	3,260,774	3,382,456	612,689	672,999	4,243,773	4,419,625	3,265,258	3,379,126	616,452	674,728

Source: The National Cancer Institute's SEER Program (URL: <http://www.seer.cancer.gov/popdata/index.html>).

**Cancer Incidence and Mortality in New Jersey, 2004-2008**

**Table 23 (continued). Population Denominators**

Hispanic Population, 2004-2008

	Male						Female					
	2004-2008	2004	2005	2006	2007	2008	2004-2008	2004	2005	2006	2007	2008
<1	72,834	14,166	13,965	14,204	15,118	15,381	70,529	13,865	13,577	13,668	14,397	15,022
01-04	271,101	50,781	53,181	54,335	55,575	57,229	260,377	48,242	50,946	52,403	53,640	55,146
05-09	279,373	52,209	53,363	55,302	57,630	60,869	266,227	49,912	50,948	52,535	54,841	57,991
10-14	261,289	52,056	52,191	52,309	52,156	52,577	249,633	49,836	49,619	50,066	49,843	50,269
15-19	259,768	49,198	50,883	52,040	53,321	54,326	244,753	46,163	47,946	49,143	50,375	51,126
20-24	286,277	58,903	57,774	57,085	56,231	56,284	245,563	49,118	48,929	48,789	48,905	49,822
25-29	327,701	63,649	65,078	65,854	66,524	66,596	269,403	52,936	53,698	53,920	54,311	54,538
30-34	318,723	61,702	62,453	63,510	64,721	66,337	268,348	53,962	53,663	53,371	53,443	53,909
35-39	297,473	57,505	58,410	59,354	60,358	61,846	269,935	53,449	53,608	54,109	54,224	54,545
40-44	272,692	51,795	53,481	54,970	55,788	56,658	259,915	50,037	51,190	52,240	52,990	53,458
45-49	222,337	39,769	42,234	44,480	46,751	49,103	221,983	40,746	42,793	44,453	45,854	48,137
50-54	165,449	29,625	30,990	32,878	34,839	37,117	174,535	31,830	33,071	34,631	36,699	38,304
55-59	125,183	22,695	24,139	25,136	26,053	27,160	138,605	25,328	26,961	27,881	28,600	29,835
60-64	89,781	16,140	16,850	17,690	18,973	20,128	104,023	18,899	19,425	20,705	21,915	23,079
65-69	66,141	12,159	12,747	13,266	13,695	14,274	79,547	14,605	15,248	15,905	16,543	17,246
70-74	45,272	8,087	8,608	9,019	9,437	10,121	59,811	10,925	11,483	11,850	12,500	13,053
75-79	30,705	5,442	5,819	6,237	6,455	6,752	43,995	7,942	8,300	8,805	9,282	9,666
80-84	17,545	2,933	3,170	3,503	3,839	4,100	28,467	4,987	5,368	5,617	6,033	6,462
85+	12,142	1,961	2,164	2,382	2,661	2,974	26,730	4,501	4,852	5,309	5,762	6,306
Total	3,421,786	650,775	667,500	683,554	700,125	719,832	3,282,379	627,283	641,625	655,400	670,157	687,914

Asian and Pacific Islanders Population, 2004-2008

	Male						Female					
	2004-2008	2004	2005	2006	2007	2008	2004-2008	2004	2005	2006	2007	2008
<1	27,192	5,424	5,357	5,345	5,495	5,571	25,559	5,058	5,050	5,013	5,221	5,217
01-04	107,888	20,491	21,451	21,630	22,063	22,253	104,636	20,153	20,849	21,143	21,153	21,338
05-09	120,922	22,551	23,167	24,223	24,863	26,118	117,003	21,966	22,524	23,197	24,141	25,175
10-14	112,105	21,619	21,923	22,450	22,904	23,209	105,453	20,022	20,491	21,136	21,704	22,100
15-19	98,083	18,628	19,184	19,533	20,106	20,632	92,542	17,567	18,044	18,491	19,010	19,430
20-24	95,642	18,942	19,086	19,175	19,166	19,273	95,698	18,983	19,118	19,220	19,156	19,221
25-29	129,154	25,643	25,773	25,070	25,813	26,855	136,996	26,970	27,487	27,166	27,517	27,856
30-34	161,186	31,705	32,270	32,297	32,378	32,536	160,470	31,257	31,789	32,158	32,473	32,793
35-39	154,583	28,498	29,494	30,805	32,251	33,535	155,879	29,206	30,088	31,118	32,262	33,205
40-44	141,224	27,010	27,681	28,454	28,895	29,184	142,945	27,273	27,923	28,666	29,252	29,831
45-49	125,468	23,408	24,553	25,219	25,727	26,561	129,341	24,361	25,292	25,950	26,494	27,244
50-54	102,481	18,589	19,273	20,360	21,592	22,667	105,460	19,173	19,865	21,002	22,177	23,243
55-59	81,395	14,545	15,623	16,451	17,041	17,735	85,732	15,448	16,677	17,407	17,768	18,432
60-64	58,995	10,608	11,040	11,708	12,401	13,238	63,118	10,943	11,667	12,467	13,492	14,549
65-69	44,253	7,722	8,417	8,828	9,452	9,834	46,187	7,995	8,567	9,249	9,953	10,423
70-74	28,064	4,582	4,937	5,628	6,158	6,759	32,422	5,661	6,109	6,460	6,871	7,321
75-79	16,736	2,798	3,064	3,287	3,639	3,948	22,631	3,999	4,246	4,519	4,827	5,040
80-84	9,794	1,645	1,801	1,972	2,098	2,278	14,365	2,432	2,672	2,896	3,089	3,276
85+	6,470	1,002	1,131	1,286	1,453	1,598	11,437	1,778	2,026	2,262	2,546	2,825
Total	1,621,635	305,410	315,225	323,721	333,495	343,784	1,647,874	310,245	320,484	329,520	339,106	348,519

Source: The National Cancer Institute's SEER Program (URL: <http://www.seer.cancer.gov/popdata/index.html>).

**Table 24. Age Distribution (%) of Incidence Cases in New Jersey, 2004-2008  
All Races, Both Sexes**

Cancer Site	0-19	20-34	35-44	45-54	55-64	65-74	75-84	85+	All Ages	Cases
All Sites	0.9%	2.3%	5.5%	13.7%	22.2%	24.5%	22.8%	8.1%	100%	233,522
Male	1.0%	1.9%	3.6%	11.6%	24.3%	27.9%	23.3%	6.5%	100%	118,029
Female	0.8%	2.8%	7.5%	15.8%	20.1%	21.0%	22.3%	9.7%	100%	115,493
Oral Cavity and Pharynx	0.5%	2.1%	6.1%	20.0%	26.8%	21.9%	16.3%	6.2%	100%	4,677
Esophagus	0.0%	0.5%	2.2%	12.4%	24.3%	27.2%	25.5%	7.9%	100%	2,316
Stomach	0.2%	1.4%	4.3%	10.6%	18.4%	23.5%	28.2%	13.6%	100%	4,043
Colon and Rectum	0.1%	0.9%	3.6%	11.2%	17.7%	23.0%	29.3%	14.2%	100%	23,990
Male	0.1%	0.8%	3.8%	12.3%	20.5%	25.4%	27.4%	9.8%	100%	11,962
Female	0.1%	1.0%	3.5%	10.2%	14.9%	20.7%	31.1%	18.6%	100%	12,028
Colon excluding Rectum	0.1%	0.8%	3.0%	9.5%	16.2%	22.9%	31.3%	16.2%	100%	17,236
Rectum	0.0%	1.1%	5.3%	15.8%	21.4%	23.3%	24.1%	9.1%	100%	6,754
Liver and Intrahepatic Bile Duct	0.7%	0.9%	2.7%	16.9%	27.6%	22.3%	22.1%	6.8%	100%	2,995
Pancreas	0.1%	0.4%	2.0%	8.9%	20.2%	23.6%	31.2%	13.6%	100%	5,992
Lung and Bronchus	0.0%	0.2%	1.7%	8.5%	20.8%	30.1%	30.4%	8.3%	100%	30,015
Male	0.0%	0.2%	1.4%	8.3%	21.9%	30.8%	30.1%	7.2%	100%	15,117
Female	0.0%	0.2%	2.0%	8.7%	19.6%	29.5%	30.7%	9.3%	100%	14,898
Bones and Joints	29.7%	15.7%	11.5%	12.8%	10.8%	8.4%	7.5%	3.5%	100%	452
Soft Tissue including Heart	6.2%	8.9%	11.9%	15.7%	15.6%	16.8%	17.2%	7.7%	100%	1,546
Melanoma of the Skin	0.7%	5.9%	10.9%	17.1%	19.8%	19.9%	18.9%	6.8%	100%	9,909
Breast	0.0%	1.7%	10.6%	22.4%	23.0%	19.5%	16.7%	6.1%	100%	32,993
Cervix Uteri	0.2%	11.3%	24.2%	26.3%	15.8%	12.3%	7.4%	2.6%	100%	2,131
Corpus and Uterus, NOS	0.0%	0.9%	4.7%	17.6%	32.5%	23.8%	15.7%	4.9%	100%	7,619
Ovary	1.0%	3.1%	7.3%	19.3%	23.5%	19.3%	18.2%	8.4%	100%	3,573
Prostate	0.0%	0.0%	0.7%	9.5%	31.2%	35.0%	19.9%	3.6%	100%	35,179
Testis	5.1%	43.5%	27.7%	16.6%	4.9%	1.5%	0.8%	0.0%	100%	1,171
Urinary Bladder	0.1%	0.4%	1.6%	6.9%	18.2%	27.4%	32.7%	12.8%	100%	12,285
Kidney and Renal Pelvis	1.2%	1.6%	6.1%	15.5%	24.5%	24.9%	20.8%	5.4%	100%	7,260
Brain and Other Nervous System	11.9%	7.0%	9.3%	15.8%	17.3%	18.0%	15.7%	5.1%	100%	3,230
Thyroid	1.6%	14.7%	21.3%	24.7%	18.2%	11.4%	6.8%	1.4%	100%	6,520
Hodgkin Lymphoma	12.0%	28.2%	15.7%	13.9%	10.4%	10.1%	7.6%	2.2%	100%	1,438
Non-Hodgkin Lymphoma	1.5%	3.7%	6.9%	13.8%	19.0%	21.1%	25.0%	9.0%	100%	9,779
Myeloma	0.0%	0.5%	3.6%	13.0%	21.0%	25.8%	26.9%	9.3%	100%	2,998
Leukemia	8.6%	3.8%	5.4%	10.8%	16.5%	19.7%	24.3%	10.9%	100%	6,061
Acute Lymphocytic Leukemia	55.6%	8.1%	4.9%	7.6%	8.4%	7.7%	5.6%	2.1%	100%	714
Chronic Lymphocytic Leukemia	0.1%	0.1%	1.6%	10.1%	19.7%	25.2%	29.1%	14.2%	100%	2,125
Acute Myeloid Leukemia	4.5%	5.0%	7.0%	11.7%	15.9%	19.1%	26.8%	10.1%	100%	1,779
Chronic Myeloid Leukemia	2.3%	7.6%	9.9%	13.6%	18.3%	19.3%	21.1%	7.9%	100%	698
Other Leukemia	3.3%	4.3%	4.9%	9.2%	9.2%	20.0%	29.8%	19.3%	100%	305
Mesothelioma	0.0%	0.3%	1.6%	5.5%	12.3%	26.2%	39.5%	14.6%	100%	706
Kaposi Sarcoma	0.0%	10.7%	24.5%	18.9%	12.0%	8.6%	15.0%	10.3%	100%	233

**Table 25. Median Age of Cancer Patients at Diagnosis, New Jersey 2004-2008  
By Primary Cancer Site, Race and Sex**

Cancer Site	All Races			Whites			Blacks		
	Total	Male	Female	Total	Male	Female	Total	Male	Female
All Sites	67	67	66	68	68	67	63	64	62
Oral Cavity and Pharynx	62	61	66	63	61	67	60	60	57
Esophagus	68	67	73	69	67	75	64	64	63
Stomach	71	69	75	72	70	76	69	68	71
Colon and Rectum	72	70	74	73	71	76	67	65	68
Colon excluding Rectum	74	72	76	75	72	77	68	67	68
Rectum and Rectosigmoid Junction	67	66	69	68	67	71	64	64	64
Liver and Intrahepatic Bile Duct	65	63	73	67	64	75	60	58	65
Pancreas	73	70	75	73	71	76	68	64	72
Lung and Bronchus	71	71	71	72	71	72	66	66	67
Bones and Joints	38	39	38	41	41	38	36	35	40
Soft Tissue including Heart	59	59	60	61	61	62	49	48	51
Melanoma of the Skin	62	65	58	63	65	59	63	68	54
Breast	61	70	61	62	71	62	58	65	58
Cervix Uteri	*	*	50	*	*	50	*	*	50
Corpus and Uterus, NOS	*	*	63	*	*	63	*	*	63
Ovary	*	*	63	*	*	63	*	*	62
Prostate	*	67	*	*	67	*	*	65	*
Testis	*	35	*	*	35	*	*	34	*
Urinary Bladder	73	73	74	73	73	75	70	69	73
Kidney and Renal Pelvis	65	64	67	66	65	68	62	60	63
Brain and Other Nervous System	58	57	60	59	58	61	51	52	50
Thyroid	49	53	48	50	53	49	51	58	50
Hodgkin Lymphoma	41	42	40	42	43	40	39	39	41
Non-Hodgkin Lymphoma	67	65	69	68	66	71	56	54	59
Myeloma	69	68	71	70	69	72	67	65	68
Leukemia	67	65	70	69	66	71	60	59	62
Acute Lymphocytic Leukemia	15	15	16	16	16	18	11	8	15
Chronic Lymphocytic Leukemia	72	70	75	73	71	75	68	65	70
Acute Myeloid Leukemia	68	68	68	69	69	70	59	54	62
Chronic Myeloid Leukemia	64	63	64	66	63	70	59	59	56
Other Leukemia	74	72	76	76	75	79	69	65	73
Mesothelioma	76	76	75	76	76	76	71	75	69
Kaposi Sarcoma	51	47	75	63	56	82	41	41	48

\* Non-applicable gender.